NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the Treatment of Sickle Cell Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Feb. (Evidence Reports/Technology Assessments, No. 165.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Hydroxyurea for the Treatment of Sickle Cell Disease

Hydroxyurea for the Treatment of Sickle Cell Disease.

Show details

Appendix D: Excluded Articles

References

  1. “Frequent flier” patients. Br. Med. J. 2005;330(7496):869 Not relevant to key questions.
  2. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Haematologica 92;77(3):204–14 Not relevant to key questions. [PubMed: 1427426]
  3. A quantitative method of assessing the health impact of different diseases in less developed countries. Ghana Health Assessment Project Team. Int J Epidemiol 81;10(1):73–80 Not relevant to key questions. [PubMed: 7239765]
  4. Aboulafia DM, Meneses M, Ginsberg S. et al. Acute myeloid leukemia in patients infected with HIV-1. AIDS. 2002;16(6):865–876. Not relevant to key questions, other, study size too small. [PubMed: 11919488]
  5. Adamson JW. Hemoglobin—from F to A, and back. N Engl J Med. 84;310(14):917–9. No Original Data. [PubMed: 6199671]
  6. Adamson R H. Activity Of Congeners Of Hydroxyurea Against Advanced Leukemia L1210. Proc Soc Exp Biol Med Not relevant to key questions, Invitro only. [PubMed: 14328917]
  7. Adeodu OO, Alimi T, Adekile AD. A comparative study of perception of sickle cell anaemia by married Nigeria rural and urban women. West Afr J Med. 2000;19(1):1–5. Not relevant to key questions. [PubMed: 10821077]
  8. Advani SH, Venugopal P, Charak BS. et al. Effect of hydroxyurea on foetal haemoglobin in myeloproliferative and myelodysplastic syndromes. Indian J Med Res Sect B Biomed Res Other Than Infect Dis. 90;92(APR.):83–85. Not relevant to key questions. [PubMed: 1695200]
  9. Ahmad A. Hydroxyurea and bronchogenic carcinoma. Australas Radiol. 74;18(4):393–7. Not relevant to key questions. [PubMed: 4462541]
  10. Ahmed S, Anwar M, Siddiqui SA. et al. Granulocyte sarcoma in patients with chronic myeloid leukaemia. J PAK MED ASSOC. 95;45(7):180–181. Not relevant to key questions, study size too small. [PubMed: 8523640]
  11. Akinyanju OO, Anionwu EN. Training of counsellors on sickle-cell disorders in Africa. LANCET. 89;1(8639):653–654. Not relevant to key questions, No Original Data, other, Not relevant to key questions. [PubMed: 2564467]
  12. Al Jam''a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 98;159(5):1642. Study size too small. [PubMed: 9554374]
  13. Al Nasir FA, Niazi G. Sickle cell disease: Patients'' awareness and management. Ann Saudi Med. 98;18(1):63–65. Not relevant to key questions. [PubMed: 17341921]
  14. Al-Arrayed S, Hafadh N, Amin S. et al. Student screening for inherited blood disorders in Bahrain. East Mediterr Health J. 2003;9(3):344–52. Not relevant to key questions. [PubMed: 15751927]
  15. Albain KS, Swinnen LJ, Erickson LC. et al. Cisplatin preceded by concurrent cytarabine and hydroxyurea: A pilot study based on in vitro model. CANCER Chemother Pharmacol. 90;27(1):33–40. Not relevant to key questions. [PubMed: 2245491]
  16. Alberts DS, Durie BG, Salmon SE. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep. 77;61(3):381–8. Study size too small. [PubMed: 872138]
  17. Alfrey C P, Karjala R J, Dale S C Et Al. Erythrokinetic Abnormalities With Administration Of Hydroxyurea (Nsc-32065). Cancer Chemother Rep Not relevant to key questions, study size too small.
  18. Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica. 2006;91(1):7–10. No Original Data. [PMC free article: PMC2204144] [PubMed: 16434364]
  19. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 95;345(8962):1392–7. Not relevant to key questions. [PubMed: 7760609]
  20. Allan NC, Shepherd PCA, Brackenridge I. et al. United Kingdom Medical Research Council randomized trial of interferon alfa in chronic-phase chronic myelogenous leukemia. SEMIN HEMATOL. 93;30(3 SUPPL. 3):20–21. Not relevant to key questions. [PubMed: 8235698]
  21. Allen A, Scoble J, Snowden S. et al. Hydroxyurea, sickle cell disease and renal transplantation. Nephron. 97;75(1):106–7. Study size too small. [PubMed: 9031282]
  22. Alleyne SI, Wint E, Serjeant GR. Psychosocial aspects of sickle cell disease. Health Soc Work. 76;1(4):104–19. Not relevant to key questions. [PubMed: 992494]
  23. al-Momen AK. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol. 91;86(1):46–8. Not relevant to key questions. [PubMed: 1950363]
  24. Alnasir FA, Skerman JH. Schoolteachers' knowledge of common health problems in Bahrain. East Mediterr Health J. 2004;10(45):537–46. Not relevant to key questions. [PubMed: 16335644]
  25. Al-Suliman A, Elsarraf NA, Baqishi M. et al. Patterns of mortality in adult sickle cell disease in the Al-Hasa region of Saudi Arabia. Ann Saudi Med. 2006;26(6):487–8. Not relevant to key questions. [PubMed: 17146211]
  26. Alter BP, Gilbert HS. The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes. Blood. 85;66(2):373–9. Study size too small. [PubMed: 2410068]
  27. Alvarez-Larran A, Cervantes F, Bellosillo B. et al. Essential thrombocythemia in young individuals: Frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218–1223. Study size too small, other. [PubMed: 17519959]
  28. Anderson-Shaw L, Orfali K. Child-to-parent bone marrow donation for treatment of sickle cell disease. J Clin Ethics. 2006;17(1):53–61. Not relevant to key questions, No Original Data. [PubMed: 16689114]
  29. Angeli-Besson C, Koeppel MC, Jacquet P. et al. Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia. Dermatology. 95;191(4):321–2. Not relevant to key questions. [PubMed: 8573931]
  30. Anie KA, Green J, Tata P. et al. Self-help manual-assisted cognitive behavioural therapy for sickle cell disease. Behav Cognitive Psychother. 2002;30(4):451–458. Not relevant to key questions.
  31. Anie KA, Steptoe A. Pain, mood and opioid medication use in sickle cell disease. Hematol J. 2003;4(1):71–3. Not relevant to key questions. [PubMed: 12692524]
  32. Anie KA. Coping with sickle cell disease: a self help manual. Arch Dis Child. 2002;86(5):385. No Original Data. [PMC free article: PMC1751111] [PubMed: 11970946]
  33. Anionwu E. Ethnic minority health. Fair provision. Nurs Stand. 95-96;10(1214):45. No Original Data. [PubMed: 8562363]
  34. Anti-cancer agents. Hydroxyurea as anti-viral therapy for brain lymphoma. TreatmentUpdate 2000;12(6):6 Not relevant to key questions, study size too small. [PubMed: 12132463]
  35. Anti-HIV agents. Long-term use of hydroxyurea. TreatmentUpdateAnti-HIV Agents: administration & dosage: adverse effects: No Original Data.
  36. Apte SV. Preventive hematology. Indian J Med Sci. 93;47(7):185–190. Not relevant to key questions. [PubMed: 8258475]
  37. Aranha GV, Grage TB. Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma. Minn Med. 77;60(8):543–8. Not relevant to key questions. [PubMed: 882082]
  38. Ariel IM. Anticancer therapy with hydrea: comparative study of daily vs. intermittent oral dosage. J Surg Oncol. 74;6(1):73–8. Not relevant to key questions. [PubMed: 4819359]
  39. Ariel IM. Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone-marrow transplants: experience with 35 patients. J Surg Oncol. 75;7(5):331–5. Not relevant to key questions. [PubMed: 1100913]
  40. Arpaci A, Aytac N, Yuregir GT. et al. An education programme on sickle cell anemia and (beta)-thalassemia for the 8th grade students. Turk J Haematol. 2003;20(1):19–24. Not relevant to key questions. [PubMed: 27265330]
  41. Ballas SK, Marcolina MJ, Dover GJ. et al. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol. 99;105(2):491–6. Study size too small. [PubMed: 10233426]
  42. Ballas SK. Attitudes toward adult patients with sickle cell disease: silent prejudice or benign neglect? J Assoc Acad Minor Phys. 96;7(3):62. No Original Data. [PubMed: 8803416]
  43. Ballas SK. Bone-marrow transplantation in sickle-cell anaemia: why so few so late? Lancet. 92;340(8829):1226. Not relevant to key questions. [PubMed: 1359294]
  44. Bamisaiye A, Bakare CG, Olatawura MO. Some social-psychologic dimensions of sickle cell anemia among Nigerians. Clin Pediatr (Phila) 74;13(1):56–9. Not relevant to key questions. [PubMed: 4809613]
  45. Barakat LP, Lutz MJ, Nicolaou DC. et al. Parental locus of control and family functioning in the quality of life of children with sickle cell disease. J Clin Psychol Med Settings. 2005;12(4):323–331. Not relevant to key questions.
  46. Barakat LP, Lutz M, Smith-Whitley K. et al. Is treatment adherence associated with better quality of life in children with sickle cell disease? Qual Life Res. 2005;14(2):407–14. Not relevant to key questions. [PubMed: 15892429]
  47. Barbarin OA. Risk and resilience in adjustment to sickle cell disease: Integrating focus groups, case reviews, and quantitative methods. J HEALTH SOC POLICY. 94;5(34):97–121. Not relevant to key questions. [PubMed: 10138766]
  48. Bardakdjian-Michau J, Guilloud-Batailie M, Maier-Redelsperger M. et al. Decreased morbidity in homozygous sickle cell disease detected at birth. Hemoglobin. 2002;26(3):211–7. Not relevant to key questions. [PubMed: 12403485]
  49. Barkow JM. In the matter of Cabrera. Issues Law Med. 89;5(3):371–2. Study size too small, No Original Data. [PubMed: 2613494]
  50. Barosi G, Besses C, Birgegard G. et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21(5):1136. Not relevant to key questions, No Original Data, other. [PubMed: 17251900]
  51. Barreiro P, de Mendoza C, Camino N. et al. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. HIV Clin Trials. 2003;4(6):361–71. Not relevant to key questions, other. [PubMed: 14628279]
  52. Barry M, Clarke S, Mulcahy F. et al. Hydroxyurea-induced neurotoxicity in HIV disease [6] AIDS. 99;13(12):1592–1594. Not relevant to key questions, other. [PubMed: 10465092]
  53. Barton C, Michael M, Richmond J. Assessment of care of children with sickle cell disease. BMJ. 90;300(6727):814. No Original Data. [PMC free article: PMC1662542] [PubMed: 2322749]
  54. Baucher H. Use of the new pneumococcal conjugate vaccine in the USA. Arch Dis Child. 2000;83(5):396. Not relevant to key questions, No Original Data. [PMC free article: PMC1718550] [PubMed: 11040145]
  55. Baudo F, Cattaneo N, Cipriani D. et al. Clinical trial of hydroxyurea in chronic myelocytic leukemia. Haematol Lat. 67;10(4):359–62. Study size too small. [PubMed: 5243231]
  56. Beckloff GL, Lerner HJ, Cole DR. et al. Hydroxyurea in bladder carcinoma. Invest Urol. 66;3(5):530–4. Study size too small. [PubMed: 5910752]
  57. Beelen DW, Graeven U, Elmaagacli AH. et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 95;85(10):2981–90. Not relevant to key questions. [PubMed: 7742558]
  58. Belgrave FZ, Gilbert SK. Health care adherence of persons with sickle cell disease. The role of social support. Ann New York Acad Sci. 89;565(-):369–370. No Original Data.
  59. Bemis EL. Sickle cell safari. Blood. 73;42(1):147–9. Not relevant to key questions. [PubMed: 4717405]
  60. Benito-Leon J, Martin E, Vincent A. et al. Neuromyotonia in association with essential thrombocythemia. J Neurol Sci. 2000;173(1):78–79. Not relevant to key questions. [PubMed: 10675583]
  61. Benkerrou M, Delarche C, Brahimi L. et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002;99(7):2297–303. Study size too small. [PubMed: 11895759]
  62. Bergman R, Friedman-Birnbaum R, Carter A. Acquired ichthyosis in a patient with polycythemia rubra vera. CUTIS. 85;36(2):157–158. Not relevant to key questions. [PubMed: 4028831]
  63. Bernardini K, Lanthaler AJ, Buratti T. et al. Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia. Am J Hematol. 2006;81(3):224–5. Not relevant to key questions. [PubMed: 16493606]
  64. Bernaudin F, Verlhac S, Coic L. et al. Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35(3):242–8. Study size too small. [PubMed: 15703901]
  65. Bezwoda WR, Nissenbaum M, Derman DP. Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate. Med Pediatr Oncol. 86;14(1):17–9. Study size too small. [PubMed: 3512970]
  66. Billings FT 3rd. Treatment of sickle cell anemia with bone marrow transplantation-pros and cons. Trans Am Clin Climatol Assoc. 89;101:8–19. discussion 19–20 No Original Data. [PMC free article: PMC2376486] [PubMed: 2486449]
  67. Binder WD, Brown DF, Nadel ES. Blurred vision, epistaxis, and fever in a young man. J Emerg Med. 2002;23(3):275–8. Not relevant to key questions. [PubMed: 12426019]
  68. Bird ST, Earp JA, Drezner SM. et al. Patient education for sickle cell disease: a national survey of health care professionals. Health Educ Res. 94;9(2):235–42. Not relevant to key questions, other. [PubMed: 10150447]
  69. Biron F, Lucht F, Peyramond D et al. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res Study size too small. [PubMed: 8721560]
  70. Blanckenberg DH, Wood R, Horban A. et al. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. AIDS. 2004;18(4):631–40. Not relevant to key questions. [PubMed: 15090768]
  71. Blau CA. Therapy for globin-chain disorders [7] NEW ENGL J MED. 93;329(5):364. No Original Data. [PubMed: 8321277]
  72. Bleyer WA, Danielson MG. Oral cancer chemotherapy in paediatric patients: Obstacles and potential for development and utilisation. Drugs. 99;58(SUPPL. 3):133–140. No Original Data. [PubMed: 10711852]
  73. Blumenreich MS, Kellihan MJ, Joseph UG. et al. Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial. Cancer. 93;71(9):2828–32. Not relevant to key questions, study size too small. [PubMed: 7682153]
  74. Bobo L, Miller ST, Smith WR. et al. Health perceptions and medical care opinions of inner-city adults with sickle cell disease or asthma compared with those of their siblings. South Med J. 89;82(1):9–12. Not relevant to key questions. [PubMed: 2911768]
  75. Boga C, Ozdogu H, Sezgin N. et al. Serum cancer antigen 15-3 concentrations in patients with sickle cell disease [2] Br J Haematol. 2006;134(5):546–547. Not relevant to key questions. [PubMed: 16856886]
  76. Bojanowski C. Use of protocols for ED patients with sickle cell anemia. J Emerg Nurs. 89;15(2 Pt 1):83–7. Not relevant to key questions. [PubMed: 2649723]
  77. Bolanos-Meade J, Lopez-Arvizu C, Cobos E. Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol. 2002;68(6):397–9. Not relevant to key questions. [PubMed: 12225400]
  78. Bolin RW, Robinson WA, Sutherland J. et al. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer. 82;50(9):1683–6. Study size too small. [PubMed: 6956430]
  79. BOLTON B H, KAUNG D T, LAWTON R L Et Al. HYDROXYUREA (NSC-32065)—A PHASE I STUDY. Cancer Chemother Rep Other. [PubMed: 14201275]
  80. Borba R, Lima CS, Grotto HZ. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy. J Clin Lab Anal. 2003;17(2):66–72. Study size too small. [PubMed: 12640630]
  81. Bourantas KL, Syrou M, Tsiara S. et al. Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia. Acta Haematol. 96;95(2):117–21. Study size too small. [PubMed: 8638440]
  82. Bowers M. Hydroxyurea. BETA 97;9–11 No Original Data.
  83. Bowman JE. Minority health issues and genetics. Community Genet. 98;1(3):142–4. No Original Data. [PubMed: 11657303]
  84. Bowman J E. Social implications of sickle cell programs. Urban Health 74;3(4):16–17+ No Original Data. [PubMed: 11662149]
  85. Britto MT, DeVellis RF, Hornung RW. et al. Health care preferences and priorities of adolescents with chronic illnesses. Pediatrics. 2004;114(5):1272–80. Not relevant to key questions. [PubMed: 15520107]
  86. Britto MT, Garrett JM, Dugliss MA. et al. Preventive services received by adolescents with cystic fibrosis and sickle cell disease. Arch Pediatr Adolesc Med. 99;153(1):27–32. Not relevant to key questions. [PubMed: 9894996]
  87. Britto MT, Garrett JM, Dugliss MA. et al. Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study. Pediatrics. 98;101(2):250–6. Not relevant to key questions. [PubMed: 9445499]
  88. Britto MT, Slap GB, DeVellis RF. et al. Specialists understanding of the health care preferences of chronically ill adolescents. J Adolesc Health. 2007;40(4):334–41. Not relevant to key questions. [PubMed: 17367726]
  89. Brodie JL. Sickle cell anemia—the disease of challenge. J Am Med Womens Assoc. 72;27(8):411–5. passim No Original Data. [PubMed: 4341979]
  90. Brooks BJ, Hanson DS, Cryer PA. et al. Erythropoietin therapy for sickle cell anemia in Jehovah''s Witnesses. South Med J. 91;84(11):1416–7. Not relevant to key questions, study size too small. [PubMed: 1948247]
  91. Brower V. The squeaky wheel gets the grease. EMBO Rep. 2005;6(11):1014–1017. No Original Data. [PMC free article: PMC1371042] [PubMed: 16264425]
  92. Brown AK, Miller ST, Agatisa P. Care of infants with sickle cell disease. Pediatrics. 89;83(5 SUPPL.):897–900. Not relevant to key questions. [PubMed: 2717325]
  93. Brown RT, Connelly M, Rittle C. et al. A longitudinal examination predicting emergency room use in children with sickle cell disease and their caregivers. J Pediatr Psychol. 2006;31(2):163–73. Not relevant to key questions. [PubMed: 16467316]
  94. Brown RT, Lambert R. Family functioning and children's adjustment in the presence of a chronic illness: Concordance between children with sickle cell disease and caretakers. Fam Syst Health. 99;17(2):165–179. Not relevant to key questions.
  95. Brugnara C, Zelmanovic D, Sorette M. et al. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol. 97;108(2):133–42. Study size too small. [PubMed: 9260753]
  96. Brunning RD. The effects of leukemia and lymphoma chemotherapy on hematopoietic cells. Am J Med Technol. 73;39(5):165–74. Not relevant to key questions, No Original Data. [PubMed: 4701364]
  97. Bunn HF. Induction of fetal hemoglobin in sickle cell disease. Blood. 99;93(6):1787–1789. No Original Data. [PubMed: 10068648]
  98. Burke SM. Hydroxyurea in sickle cell disease. MCN Am J Matern Child Nurs. 96;21(4):210. No Original Data. [PubMed: 8754440]
  99. Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol. 86;85(3):337–341. Not relevant to key questions, study size too small. [PubMed: 3790210]
  100. Caccialanza P, Finzi A F. Clinical and experimental investigations on the effect of cytostatic drugs in psoriasis. Ital Gen Rev Dermatol Not relevant to key questions.
  101. Campbell PJ, Green AR. The long-term outlook for essential thrombocythemia. Mayo Clin Proc. 2006;81(2):157–158. No Original Data. [PubMed: 16471067]
  102. Candoni A, Tiribelli M, Fanin R. Plasma cell leukemia occuring in a patient with thrombocythemia treated with hyroxyurea and busulphan. Leuk Lymphoma. 2004;45(4):821–824. Not relevant to key questions. [PubMed: 15160964]
  103. Candoni A, Tiribelli M, Fanin R. Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan. Leuk Lymphoma Not relevant to key questions, other. [PubMed: 15160964]
  104. Carella AM, Frassoni F. ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia. Br J Haematol. 96;95(1):213–5. Not relevant to key questions, No Original Data. [PubMed: 8857964]
  105. Carella AM. Mini-ICE protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia [1] Leuk Lymphoma. 98;31(34):437–438. Not relevant to key questions, study size too small, No Original Data. [PubMed: 9869211]
  106. Carr A, Hudson J, Chuah J. et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15(14):1811–22. Other. [PubMed: 11579243]
  107. Cassileth PA, Hyman GA. Treatment of malignant melanoma with hydroxyurea. Cancer Res. 67;27(10):1843–5. Study size too small. [PubMed: 6064961]
  108. Cassileth PA. Intensive therapy in elderly patients with acute myeloid leukemia. J Clin Oncol. 90;8(5):937–8. Not relevant to key questions, No Original Data. [PubMed: 2332774]
  109. Catlin A. The dilemma of Jehovah's Witness children who need blood to survive. HEC Forum. 96;8(4):195–207. discussion 208–11 Not relevant to key questions. [PubMed: 10159895]
  110. Cepeda J A, Wilks D. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection. AIDS Not relevant to key questions, other. [PubMed: 10716516]
  111. Chang YH, Lu MY, Jou ST. et al. Forty-seven children suffering from chronic myeloid leukemia at a center over a 25-year period. Pediatr Hematol Oncol. 2003;20(7):505–15. Not relevant to key questions. [PubMed: 12959855]
  112. Charache S. Experimental therapy of sickle cell disease. Use of hydroxyurea. Am J Pediatr Hematol Oncol. 94;16(1):62–6. No Original Data. [PubMed: 7508689]
  113. Charche S. Sickle-cell anemia: the known and the unknown. Ann Intern Med. 72;77(1):148–9. No Original Data. [PubMed: 5052438]
  114. Chernoff RG, Ireys HT, DeVet KA. et al. A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Arch Pediatr Adolesc Med. 2002;156(6):533–9. Not relevant to key questions. [PubMed: 12038883]
  115. Cheung AYC, Browne B, Capen C. Hydroxyurea-induced fever in cervical carcinoma: Case report and review of the literature. Cancer Invest. 99;17(4):245–248. Not relevant to key questions. [PubMed: 10225002]
  116. Cheung M C, Hicks L K, Pendergrast J. Thrombocytosis. N Engl J Med No Original Data.
  117. Chistolini A, Gabriella Muzzucconi M, Ferrari A. et al. Essential thrombocythemia: A retrospective study on the clinical course of 100 patients. Haematologica. 90;75(6):537–540. Not relevant to key questions. [PubMed: 2098295]
  118. Choo D, McHenry P. Combination therapy with acitretin and hydroxyurea for severe psoriasis [1] J Dermatol Treat. 99;10(1):71–72. Not relevant to key questions.
  119. Clare N. Management of sickle cell disease. Management would improve if doctors listened more to patients. BMJ. 98;316(7135):935. No Original Data. [PubMed: 9569399]
  120. Clarke PC, Clare NR. Sickle cell anaemia: a challenge for health education. Health Educ J. 81;40(2):50–2. Not relevant to key questions, No Original Data. [PubMed: 10252326]
  121. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood. 96;88(6):1951–3. Study size too small. [PubMed: 8822912]
  122. Cobo F, Cervantes F, Martinez C. et al. Multiple myeloma following essential thrombocythemia. LEUK LYMPHOMA. 95;20(12):177–179. Not relevant to key questions. [PubMed: 8750643]
  123. Cole D R, Beckloff G L, Rousselot L M. Clinical Results With Hydroxyurea In Cancer Chemotherapy; Preliminary Report. N Y State J Med 65;652132–6 Study size too small. [PubMed: 14335187]
  124. Collier AC, Schwartz MA. Strategies for second-line antiretroviral therapy in adults with HIV infection. Adv Exp Med Biol. 99;458(-):239–266. No Original Data. [PubMed: 10549396]
  125. Combinations studied for sickle cell disease. AM. PHARM. 93;33(6):15–16 No Original Data.
  126. Comer EW. Integrating the health and mental health needs of the chronically ill: a group for individuals with depression and sickle cell disease. Soc Work Health Care. 2004;38(4):57–76. Not relevant to key questions. [PubMed: 15149906]
  127. Conkle C. Patient allegedly abandoned by physicians and hospital. J Ark Med Soc. 93;89(11):547–51. Not relevant to key questions. [PubMed: 8486589]
  128. Connelly M, Wagner JL, Brown RT. et al. Informant discrepancy in perceptions of sickle cell disease severity. J Pediatr Psychol. 2005;30(5):443–8. Not relevant to key questions. [PubMed: 15944172]
  129. Conran N, Fattori A, Saad ST. et al. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am J Hematol. 2004;76(4):343–7. Study size too small. [PubMed: 15282666]
  130. Conran N, Oresco-Santos C, Acosta HC. et al. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol. 2004;124(4):547–54. Study size too small, other. [PubMed: 14984506]
  131. Conyard S, Krishnamurthy M, Dosik H. Psychosocial aspects of sickle-cell anemia in adolescents. Health Soc Work. 80;5(1):20–6. No Original Data. [PubMed: 7364335]
  132. Conyard S, Krishnamurthy M, Dosik H. Psychosocial aspects of sickle-cell anemia in adolescents. Health Soc Work. 80;5(1):20–6. Not relevant to key questions, No Original Data. [PubMed: 7364335]
  133. Cortes J, Kantarjian H, O'Brien S. et al. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med. 96;100(4):452–5. Not relevant to key questions, study size too small. [PubMed: 8610733]
  134. Covas DT, de Lucena Angulo I. et al. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica. 2004;89(3):273–80. Study size too small. [PubMed: 15020264]
  135. Crawford M. The multicultural society. Sickle cell disease in children. Nursing (Lond) 91;4(31):23–5. No Original Data. [PubMed: 2023682]
  136. Crawford S. Hydroxyurea information for children and parents. Paediatric Nursing. 2003;15(2):40. No Original Data. [PubMed: 12677858]
  137. Creasey WA, Capizzi RL, DeConti RC. Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065) Cancer Chemother Rep. 70;54(3):191–4. Study size too small. [PubMed: 4946005]
  138. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders +AFs-3+AF0- Br J Haematol. 2005;128(5):734–736. Not relevant to key questions. [PubMed: 15725099]
  139. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol. 2005;128(5):734–6. Study size too small. [PubMed: 15725099]
  140. Cusimano MD. Hydroxyurea for treatment of meningioma. J Neurosurg. 98;88(5):938–9. Not relevant to key questions, No Original Data. [PubMed: 9576275]
  141. Dahl M G, Comaish J S. Long-term effects of hydroxyurea in psoriases. Br Med Study size too small. [PMC free article: PMC1786814] [PubMed: 4643395]
  142. Dalton RN, Turner C, Dick M. et al. The measurement of urinary hydroxyurea in sickle cell anaemia. Br J Haematol. 2005;130(1):138–44. Study size too small, Not relevant to key questions. [PubMed: 15982356]
  143. Dames-Fincher G. A patient''s perspective on sickle cell disease treatment. J Natl Med Assoc. 92;84(9):739–741. No Original Data. [PMC free article: PMC2571780] [PubMed: 1404470]
  144. Dampier C, Ely E, Brodecki D. et al. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol. 2002;24(8):643–7. Not relevant to key questions. [PubMed: 12439036]
  145. Davey RJ. Lead poisoning and sickle cell anemia programs at neighborhood health centers: a survey. Med Care. 74;12(9):788–94. Not relevant to key questions. [PubMed: 4414069]
  146. Davidoff A, Kenney G, Dubay L. Effects of the State Children's Health Insurance Program Expansions on children with chronic health conditions. Pediatrics. 2005;116(1):e34–42. Not relevant to key questions. [PubMed: 15958662]
  147. Davies SC, Bevan DH. Sickle cell pain crisis. Lancet. 96;347(8996):263. No Original Data, other. [PubMed: 8551907]
  148. Davies SC, Roberts IA. Bone marrow transplant for sickle cell disease—an update. Arch Dis Child. 96;75(1):3–6. Not relevant to key questions, No Original Data, other. [PMC free article: PMC1511667] [PubMed: 8813862]
  149. Davies S. Bone marrow transplantation for sickle cell anaemia. Br J Hosp Med. 93;49(4):229. Not relevant to key questions, No Original Data. [PubMed: 8443620]
  150. Davis H, Gergen PJ, Moore RM. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep. 97;112(1):52–8. Not relevant to key questions. [PMC free article: PMC1381839] [PubMed: 9018289]
  151. Day SW. Development and evaluation of a sickle cell assessment instrument. Pediatr Nurs. 2004;30(6):451–8. Not relevant to key questions. [PubMed: 15704592]
  152. De Bergsagel, De Frenkel E P, Alfrey C P Et Al. Megaloblastic Erythropoiesis Induced By Hydroxyurea (NSC-32065). Cancer No Original Data, other. [PubMed: 14206906]
  153. de Montalembert M, Bachir D, Hulin A. et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica. 2006;91(12):1685–8. Not relevant to key questions. [PubMed: 17145606]
  154. de Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood. 2001;98(9):2878–9. No Original Data. [PubMed: 11697339]
  155. De Oliveira FM, Scrideli CA, Tone LG. A case of near-triploid with t(2;14)(p12;q32) in blast crisis of chronic myeloid leukemia detected by spectral karyotyping (SKY) [2] J Pediatr Hematol Oncol. 2007;29(4):274–276. Not relevant to key questions. [PubMed: 17414573]
  156. de Paula EV, Lima CS, Arruda VR. et al. Long-term hydroxyurea therapy in beta-thalassaemia patients. Eur J Haematol. 2003;70(3):151–5. Study size too small. [PubMed: 12605659]
  157. Desimone J. Introduction: The evolving role of DNA demethylating agents in the treatment of sickle cell disease and thalassemia. Semin Hematol. 2004;41(SUPPL. 6):1–2. No Original Data. [PubMed: 15799099]
  158. DeVet KA, Ireys HT. Psychometric properties of the maternal worry scale for children with chronic illness. J Pediatr Psychol. 98;23(4):257–66. Not relevant to key questions. [PubMed: 9718899]
  159. Diggs LW, Flowers E. Sickle cell anemia in the home environment. Observations on the natural history of the disease in Tennessee children. Clin Pediatr (Phila) 71;10(12):697–700. Not relevant to key questions. [PubMed: 5139946]
  160. Dive C, Evans CA, Owen PJ. et al. Abelson tyrosine kinase activation suppresses apoptosis in haemopoietic cells deprived of interleukin 3 (IL-3) or treated with hydroxyurea. LEUKEMIA. 93;7(5):775. Not relevant to key questions, Invitro only.
  161. Dohrenwend A, Sehgal R. Lost between the cracks: pain patients denied inpatient treatment for illicit drug addiction. Psychosom Med. 2005;67(4):677–8. No Original Data. [PubMed: 16046387]
  162. Donovan PB, Berk PD, Goldberg JD. Hydroxyurea, an effective agent for the treatment of polycythemia vera. CLIN RES. 82;30(2):315A. Not relevant to key questions, other.
  163. Dorsey CJ, Murdaugh CL. The theory of self-care management for vulnerable populations. Journal of Theory Construction & Testing. 2003;7(2):43. Not relevant to key questions, No Original Data.
  164. Doswell W M. Sickle cell anemia: you can do something to help. Nursing 78;8(4):65, 67–8, 70 No Original Data. [PubMed: 246185]
  165. Dover G J, Charache S, Boyer S H. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea. Trans Assoc Am Physicians 84;97140–5 Not relevant to key questions, other, study size too small. [PubMed: 6085527]
  166. Dover GJ, Charache S, Nora R. et al. Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea. Ann N Y Acad Sci. 85;445:218–24. No Original Data. [PubMed: 2409873]
  167. Dover GJ, Charache S. The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease. Prog Clin Biol Res. 87;240:277–85. Study size too small. [PubMed: 2441416]
  168. Dover GJ, Humphries RK, Moore JG. et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood. 86;67(3):735–8. Study size too small. [PubMed: 2418898]
  169. Dowling M D, Haghbin M, Gee T S et al. Comparative results obtained in the treatment of acute leukemia. Recent Results Cancer Res 73;43133–44 Not relevant to key questions.
  170. Driscoll MC, Lerner N, Anyane-Yeboa K. Prenatal diagnosis of sickle hemoglobinopathies: The experience of the Columbia University Comprehensive Center for Sickle Cell Diseases. AM J HUM GENET. 87;40(6):548–558. Not relevant to key questions. [PMC free article: PMC1684158] [PubMed: 3035920]
  171. D''Sa S, Parker N, Ware M A et al. Fast track admission for children with sickle cell crises. Opiates other than pethidine are better (multiple letters) +AFs-2+AF0-. Br. Med. J. 98;316(7135):+AFs-d+AF0-934, 935 No Original Data. [PubMed: 9569397]
  172. Duckett CL. Caring for children with sickle cell anemia. Children. 71;18(6):227–31. No Original Data. [PubMed: 5119899]
  173. Dukes-Hamilton C S. Antiretroviral Activity Of Hydroxyurea Alone And In Combination With Ddi. Not relevant to key questions.
  174. Dula A. African American suspicion of the healthcare system is justified: what do we do about it? Camb Q Healthc Ethics. 94;3(3):347–57. Not relevant to key questions, No Original Data. [PubMed: 7994458]
  175. Dumaplin CA. Pediatric pharmacology. Avoiding admission for afebrile pediatric sickle cell pain: pain management methods. Journal of Pediatric Healthcare. 2006;20(2):115. No Original Data. [PubMed: 16522488]
  176. Elander J, Lusher J, Bevan D. et al. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage. 2004;27(2):156–69. Not relevant to key questions. [PubMed: 15157040]
  177. Embury SH. New treatments of sickle cell disease. West J Med. 96;164(5):444. No Original Data. [PMC free article: PMC1303549] [PubMed: 8686307]
  178. Feldman L, Allen S, Westerman M. et al. Long-term use of hydroxyurea for sickle cell anemia. JAMA. 2003;290(6):752–3. author reply 754 No Original Data. [PubMed: 12915423]
  179. Fielding J, Batalden P, Tolbert G. et al. A coordinated sickle cell program for economically disadvantaged adolescents. Am J Public Health. 74;64(5):427–32. Not relevant to key questions. [PMC free article: PMC1775436] [PubMed: 4855495]
  180. Finazzi G, Ruggeri M, Rodeghiero F. et al. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis [1] Blood. 2003;101(9):3749. Not relevant to key questions, No Original Data. [PubMed: 12707224]
  181. Finch SC. Sickle cell survey. Conn Med. 73;37(9):460–1. Not relevant to key questions, No Original Data. [PubMed: 4746171]
  182. First reports of adverse drug reactions (ADRs) in recent weeks. Drugs Ther. Perspect. 2001;17(4):15 Not relevant to key questions, No Original Data.
  183. Fithian JH. Sickle cell disease education at the Children''s Hospital of Philadelphia. J Sch Health. 92;62(8):388–91. Not relevant to key questions. [PubMed: 1479833]
  184. Flanagan C. Home management of sickle cell anemia. Pediatr Nurs. 80;6(2):A–D. Not relevant to key questions, No Original Data. [PubMed: 6899029]
  185. Fletcher C. Appraisal and coping with vaso-occlusive crisis in adolescents with sickle cell disease. Pediatr Nurs. 2000;26(3):319–24. Not relevant to key questions. [PubMed: 12026399]
  186. Flexner C W. Trial Of Hydroxyurea In Combo With Antivirals In Hiv. Not relevant to key questions.
  187. Flexner C, Bartlett J G. Complications of HIV therapy. Hopkins HIV No Original Data.
  188. Flores F, Eaglstein WA, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf [4] Ann Intern Med. 2000;132(5):417. Not relevant to key questions. [PubMed: 10691597]
  189. Foa P, Iurlo A, Saglio G. et al. Chronic neutrophilic leukaemia associated with polycythemia vera: Pathogenetic implications and therapeutic approach. BR J HAEMATOL. 91;78(2):286–288. Not relevant to key questions. [PubMed: 2064971]
  190. Foley KM, Portenoy RK, Rosenbloom BE. et al. Treatment of pain in sickle-cell crisis +AFs-5+AF0- NEW ENGL J MED. 94;331(5):334–335. Not relevant to key questions, No Original Data. [PubMed: 8068115]
  191. Foli A, Lori F, Maserati R. et al. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antivir Ther. 97;2(1):31–8. Study size too small, other. [PubMed: 11322264]
  192. Forbes K, Forbes B, Lee A. Re: Sicle cell-related pain: Perceptions of medical practitioners +AFs-2+AF0- J Pain Symptom Manage. 98;15(6):333. No Original Data. [PubMed: 9670633]
  193. Fost N. Ethical problems in pediatrics. Curr Probl Pediatr. 76;6(12):1–31. Not relevant to key questions, No Original Data. [PubMed: 991621]
  194. Fowler MG, Whitt JK, Lallinger RR. et al. Neuropsychologic and academic functioning of children with sickle cell anemia. J Dev Behav Pediatr. 88;9(4):213–220. Not relevant to key questions. [PubMed: 3216001]
  195. France-Dawson M. Sickle cell conditions and health knowledge. Nurs Stand. 90;4(35):30–4. No Original Data. [PubMed: 2136266]
  196. Fred HL. Cause or coincidence? South Med J. 92;85(9):923. Not relevant to key questions. [PubMed: 1523455]
  197. Frenkel E P, Skinner W N, Smiley J D. Studies On A Metabolic Defect Induced By Hydroxyurea (Nsc-32065). Cancer Chemother Rep Invitro only. [PubMed: 14206907]
  198. Frequency of sickle cell crises cut by hydroxyurea use. Am J Health Syst Pharm 95;52(8):778 No Original Data. [PubMed: 7634104]
  199. Friedman SA. The diagnosis and medical management of vascular ulcers. Clin Dermatol. 90;8(34):30–39. No Original Data. [PubMed: 2129948]
  200. Fucharoen S, Siritanaratkul N, Winichagoon P. et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood. 96;87(3):887–92. Not relevant to key questions. [PubMed: 8562958]
  201. Fuggle P, Shand PA, Gill LJ. et al. Pain, quality of life, and coping in sickle cell disease. Arch Dis Child. 96;75(3):199–203. Not relevant to key questions. [PMC free article: PMC1511691] [PubMed: 8976657]
  202. Fuller J, Davis P, Dancer J. et al. Comparison of attitudes about communication in children and adolescents with sickle cell disease. Percept Mot Skills. 98;87(2):634. Not relevant to key questions. [PubMed: 9842615]
  203. Gale RP, Hehlmann R, Zhang MJ. et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 98;91(5):1810–9. Not relevant to key questions. [PubMed: 9473250]
  204. Galesic K, Bozic B, Racic I. et al. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia. Nephrology (Carlton) 2006;11(1):49–52. Not relevant to key questions. [PubMed: 16509932]
  205. Galton D A. Chemotherapy of chronic myelocytic leukemia. Semin Hematol No Original Data. [PubMed: 4900650]
  206. Gamberini MR, Fortini M, De Sanctis V. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatr Endocrinol Rev. 2004;2(Suppl 2):319–22. Not relevant to key questions. [PubMed: 16462721]
  207. Gambero S, Canalli AA, Traina F. et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur J Haematol. 2007;78(2):144–51. Study size too small. [PubMed: 17313560]
  208. Gandhi V, Plunkett W, Kantarjian H. et al. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 98;16(7):2321–31. Not relevant to key questions. [PubMed: 9667246]
  209. Garcí a F, Plana M, Arnedo M et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS Study size too small. [PubMed: 12478068]
  210. Gartstein MA, Short AD, Vannatta K. et al. Psychosocial adjustment of children with chronic illness: an evaluation of three models. J Dev Behav Pediatr. 99;20(3):157–63. Not relevant to key questions. [PubMed: 10393072]
  211. Gary LE. The sickle cell controversy. Soc Work. 74;19(3):263–72. No Original Data. [PubMed: 11662129]
  212. Geddes EW, Falkson G. Malignant hepatoma in the Bantu. Cancer. 70;25(6):1271–8. Study size too small. [PubMed: 4192938]
  213. Gentry BF, Dancer J. Public school speech-language pathologists'' knowledge of sickle cell disease. Percept Mot Skills. 98;86(3 Pt 1):1034. Not relevant to key questions. [PubMed: 9656303]
  214. Gentry B, Goodwin A, Dancer J. Knowledge of sickle cell disease among specialists in communicative disorders in medical settings. Percept Mot Skills. 97;85(3 Pt 2):1394. Not relevant to key questions. [PubMed: 9450298]
  215. Gil KM, Anthony KK, Carson JW. et al. Daily coping practice predicts treatment effects in children with sickle cell disease. J Pediatr Psychol. 2001;26(3):163–73. Not relevant to key questions. [PubMed: 11259518]
  216. Gil KM, Carson JW, Porter LS. et al. Daily stress and mood and their association with pain, health-care use, and school activity in adolescents with sickle cell disease. J Pediatr Psychol. 2003;28(5):363–73. Not relevant to key questions. [PubMed: 12808013]
  217. Gil KM, Phillips G, Abrams MR. et al. Pain drawings and sickle cell disease pain. Clin J Pain. 90;6(2):105–9. Not relevant to key questions. [PubMed: 2135002]
  218. Gil KM, Thompson RJ, Keith BR. et al. Sickle cell disease pain in children and adolescents: change in pain frequency and coping strategies over time. J Pediatr Psychol. 93;18(5):621–37. Not relevant to key questions. [PubMed: 8295083]
  219. Gil KM, Wilson JJ, Edens JL. et al. Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African American adults with sickle cell disease. Health Psychol. 96;15(1):3–10. Not relevant to key questions. [PubMed: 8788535]
  220. Gill FM, Brown A, Gallagher D. et al. Newborn experience in the Cooperative Study of Sickle Cell Disease. Pediatrics. 89;83(5 Pt 2):827–9. Not relevant to key questions. [PubMed: 2654872]
  221. Gill LJ, Shand PAX, Fuggle P. et al. Pain assessment for children with sickle cell disease: Improved validity of diary keeping versus interview ratings. BR J HEALTH PSYCHOL. 97;2(2):131–140. Not relevant to key questions.
  222. Giordano PC, Bouva MJ, Harteveld CL. A confidential inquiry estimating the number of patients affected with sickle cell disease and thalassemia major confirms the need for a prevention strategy in the Netherlands. Hemoglobin. 2004;28(4):287–96. Not relevant to key questions. [PubMed: 15658185]
  223. Gladwin MT, Rodgers GP. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet. 2000;355(9214):1476–8. No Original Data. [PubMed: 10801164]
  224. Gladwin MT, Shelhamer JH, Ognibene FP. et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116(2):436–44. Study size too small. [PubMed: 11841449]
  225. Glover RE, Ivy ED, Orringer EP. et al. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol. 99;55(6):1006–10. Study size too small. [PubMed: 10347241]
  226. Golden WE, Moore G. Sickle cell syndromes: misdiagnosis can affect treatment. J Ark Med Soc. 2004;101(5):144–5. Not relevant to key questions. [PubMed: 15554178]
  227. Goldin A, Venditti J M, Mead J A Et Al. Antileukemic Activity Of Hydroxyurea (Nsc-32065) And Other Urea Derivatives. Cancer Other. [PubMed: 14206921]
  228. Gortner C. Hydroxyurea. BETA 98;7 No Original Data.
  229. Gottlieb JA, Frei E 3rd, Luce JK. Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma. Cancer Chemother Rep. 71;55(3):277–80. Study size too small, Not relevant to key questions. [PubMed: 5115848]
  230. Gramvussakis S, George SA. Chronic actinic dermatitis (photosensitivity dermatitis/actinic reticuloid syndrome): Beneficial effect from hydroxyurea [17] Br J Dermatol. 2000;143(6):1340. Not relevant to key questions. [PubMed: 11122059]
  231. Granel B, Serratrice J, Bouabdallah R. et al. Atypical porphyria cutanea tarda in a patient with chronic myelogenous leukemia [2] Dermatology. 2001;203(1):82–83. Not relevant to key questions. [PubMed: 11549809]
  232. Green BT, Branch MS. Ischemic colitis in a young adult during sickle cell crisis: Case report and review. Gastrointest Endosc. 2003;57(4):605–607. Study size too small, Not relevant to key questions. [PubMed: 12665783]
  233. Griesshammer M, Arnold R, Bangerter M. et al. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol. 98;61(1):7–13. Not relevant to key questions. [PubMed: 9688286]
  234. Griffith K M. Hydroxyurea (Nsc-32065): Results Of A Phase I Study. Cancer Chemother Not relevant to key questions, other. [PubMed: 14206912]
  235. Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med. 77;137(9):1246–7. Not relevant to key questions, study size too small. [PubMed: 268956]
  236. Grunke M, Dechant C, Lö w P et al. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection. J Acquir Immune Defic Syndr Not relevant to key questions, study size too small. [PubMed: 10458626]
  237. Guarini L, Piomelli S, Poh-Fitzpatrick MB. Hydroxyurea in congenital erythropoietic porphyria [7] NEW Engl J Med. 94;330(15):1091–1092. Not relevant to key questions. [PubMed: 8127351]
  238. Guilhot F, Lamagnere JP, Harousseau JL. et al. A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results. Eur J Cancer. 91;27(Suppl 4):S26. Not relevant to key questions. [PubMed: 1799470]
  239. Gulati SC, Vega R, Gee T. Growth and development of children born to patients after cancer therapy. Cancer Invest. 86;4(3):197–205. Not relevant to key questions. [PubMed: 3719409]
  240. Gullattee AC. Medico-legal insurance implications of sickle cell anemia. J Natl Med Assoc. 73;65(5):415–9. No Original Data. [PMC free article: PMC2609215] [PubMed: 4744055]
  241. Gupta P. Bone marrow transplantation for sickle cell anemia: is it the right choice? Indian Pediatr. 97;34(5):460–2. Not relevant to key questions. [PubMed: 9332129]
  242. Guthrie T. Hydroxyurea for sickle cell. P T. 95;20(7):497–498. No Original Data.
  243. Hagar W. Long-term use of hydroxyurea for sickle cell anemia. JAMA. 2003;290(6):753. author reply 754 No Original Data. [PubMed: 12915424]
  244. Hampton ML, Anderson J, Lavizzo BS. et al. Sickle cell “nondisease”. A potentially serious public health problem. Am J Dis Child. 74;128(1):58–61. Not relevant to key questions. [PubMed: 4834985]
  245. Handa H, Akiba T, Yoshida Y. et al. Development of bilateral malleolus skin ulcers during hydroxyurea treatment in an elderly patient with chronic myelogenous leukemia. Kitakanto Med J. 98;48(2):167–169. Other.
  246. Harrington P, Clarke S, Ryan M et al. Efficacy and tolerability of didanosine-hydroxyurea containing regimens in a cohort of heavily antiretroviral experienced patients. Not relevant to key questions.
  247. Harris M S. Genetic disease programs and the black community. Urban Health 79;8(8):40, 42–3, 54 No Original Data. [PubMed: 10244459]
  248. Harrison PV. Drugs and side-effects. Clin Exp Dermatol. 90;15(1):77–78. Not relevant to key questions, other. [PubMed: 2311293]
  249. Hassan A, Jam''a A, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 98;159(5):1642. Study size too small. [PubMed: 9554374]
  250. Hassan HT, Zyada LE. Treatment with recombinant human interferon alpha plus low dose cytarabine with or without hydroxyurea for acute monoblastic leukaemia. Hematol Rev Commun. 93;7(3):125–131. Not relevant to key questions, study size too small.
  251. Hawkins MR, Diehl-Svrjcek B, Dunbar LJ. Caring for children with special healthcare needs in the managed care environment. Lippincotts Case Manag. 2006;11(4):216–23. Not relevant to key questions. [PubMed: 16926694]
  252. Hazzard A, Celano M, Collins M. et al. Effects of STARBRIGHT World on knowledge, social support, and coping in hospitalized children with sickle cell disease and asthma. Child Health Care. 2002;31(1):69–86. Not relevant to key questions.
  253. Hehlmann R, Anger B, Messerer D. et al. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut. 88;56(2):87–91. Not relevant to key questions. [PubMed: 3277680]
  254. Hehlmann R, Berger U, Pfirrmann M. et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686–4692. Not relevant to key questions. [PubMed: 17317858]
  255. Hehlmann R, Heimpel H, Griesshammer M. et al. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group. Leukemia. 92;6(Suppl 3):110S–114S. Not relevant to key questions, No Original Data. [PubMed: 1602805]
  256. Hehlmann R, Heimpel H, Hasford J. et al. Randomized comparison of interferon-(alpha) with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 94;84(12):4064–4077. Not relevant to key questions. [PubMed: 7994025]
  257. Hehlmann R, Heimpel H, Hasford J. Randomized comparison of interferon-(alpha), hydroxyurea, and busulfan in chronic myeloid leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani [7] BLOOD. 95;85(10):3000–3002. Not relevant to key questions, No Original Data.
  258. Hehlmann R, Heimpel H, Hossfeld DK. et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II) Bone Marrow Transplant. 96;17(SUPPL. 3):S21–S24. Not relevant to key questions, other. [PubMed: 8769695]
  259. Hehlmann R, Heimpel H, Kolb HJ. et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma. 93;11(Suppl 1):159–68. Other. [PubMed: 8251890]
  260. Heimler A, Chabot A. Sickle cell counseling in a children and youth project. Am J Public Health. 74;64(10):995–7. Not relevant to key questions. [PMC free article: PMC1775735] [PubMed: 4415768]
  261. Heller P, Komblihtt LI, Cuello MT. et al. BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance [5] Blood. 2001;98(6):1990. Not relevant to key questions. [PubMed: 11565540]
  262. Hellmann K. Investigational drugs for the treatment of malignant melanoma. Proc R Soc Med. 74;67(2):100–1. Not relevant to key questions. [PMC free article: PMC1645249] [PubMed: 4821219]
  263. Helton KJ, Wang WC, Wynn LW. et al. The effect of hydroxyurea on vasculopathy in a child with sickle cell disease. AJNR Am J Neuroradiol. 2002;23(10):1692–6. Study size too small. [PubMed: 12427625]
  264. Hendrickse RG, Barnes PM. Sickle cell anaemia: report of a therapeutic trial. West Afr Med J. 66;15(2):55–64. Not relevant to key questions. [PubMed: 5326524]
  265. Hermans P, De Wit S, Sommereijns B. et al. Use of hydroxyurea in heavily pretreated patients with HIV infection. Antivir Ther. 99;4(Suppl 3):19–22. Not relevant to key questions, other. [PubMed: 16021867]
  266. Hernandez JM, Orfao A, Gonzalez M. et al. Immunophenotypic characterisation of acute leukaemia after polycythemia vera. J Clin Pathol. 93;46(7):668–71. Not relevant to key questions. [PMC free article: PMC501400] [PubMed: 8157758]
  267. Herron S, Bacak SJ, King A. et al. Inadequate recognition of education resources required for high-risk students with sickle cell disease. Arch Pediatr Adolesc Med. 2003;157(1):104. Not relevant to key questions. [PubMed: 12517203]
  268. Hilbe W, Apfelbeck U, Fridrik M. et al. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res. 98;22(10):881–6. Not relevant to key questions, No Original Data. [PubMed: 9766747]
  269. Ho PTC, Murgo AJ, Silver RT. et al. Hydroxyurea and sickle cell crisis [2] NEW ENGL J MED. 95;333(15):1008–1009. No Original Data. [PubMed: 7666902]
  270. Ho PT, Murgo AJ. Hydroxyurea and sickle cell crisis. N Engl J Med. 95;333(15):1008. author reply 1009 No Original Data. [PubMed: 7666902]
  271. Hobbs JR, Obaro SK. Bone marrow transplantation in sickle cell disease. Lancet. 93;342(8883):1362–3. No Original Data. [PubMed: 7901652]
  272. Hofmann M, de Montalembert M, Beauquier-Maccotta B. et al. Posttraumatic stress disorder in children affected by sickle-cell disease and their parents. Am J Hematol. 2007;82(2):171–2. Not relevant to key questions. [PubMed: 16924639]
  273. Holtzman NA. The impact of the federal cutback on genetic services. Am J Med Genet. 83;15(2):353–71. Not relevant to key questions, No Original Data. [PubMed: 6881206]
  274. Horan J, Lerner N. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(21):1612–3. No Original Data. [PubMed: 10841686]
  275. How safe is hydroxyurea in the treatment of polycythemia vera?. Haematologica 99;84(8):673–674 Not relevant to key questions, No Original Data. [PubMed: 10457399]
  276. Hsiao E, Charles R, Magid C. et al. An unusual development. Am J Med. 2005;118(6):609–11. Not relevant to key questions. [PubMed: 15922691]
  277. Hu Y H, Ruckenstein E. Tunable Delocalization of Unpaired Electrons of Nitroxide Radicals for Sickle-Cell Disease Drug Improvements. J Phys Chem B 2007; Not relevant to key questions. [PubMed: 17429996]
  278. Hubbard R. Transparent women, visible genes, and new conceptions of disease. Camb Q Healthc Ethics. 95;4(3):291–5. No Original Data. [PubMed: 7551141]
  279. Huguley CM. Chronic myelocytic and chronic lymphocytic leukemia. Cancer. 72;30(6):1583–7. No Original Data, other. [PubMed: 4509107]
  280. Hurtig AL, Koepke D, Park KB. Relation between severity of chronic illness and adjustment in children and adolescents with sickle cell disease. J Pediatr Psychol. 89;14(1):117–132. Not relevant to key questions. [PubMed: 2723954]
  281. Huynh TH, Johnson MW, Hackel RE. Bilateral proliferative retinopathy in chronic myelogenous leukemia. Retina. 2007;27(1):124–125. Not relevant to key questions. [PubMed: 17218931]
  282. Hwang WL, Gau JP, Chen MC. et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: Successful control of hyperleukocytosis and leukostasis syndrome with leukaphereses and hydroxyurea [2] AM J HEMATOL. 93;43(4):323–324. Not relevant to key questions. [PubMed: 8372818]
  283. Hydroxyurea (Droxia/Hydrea/Mylocel). Clinical JTurnal of Oncology Nursing 2003;7(6):57 No Original Data.
  284. Hydroxyurea 100 mg/mL. Int. J. Pharm. Compd. 2006;10(5):384 Not relevant to key questions, No Original Data.
  285. Hydroxyurea combinations. AIDS Patient Care 95;9(2):87 No Original Data.
  286. Hydroxyurea in HIV therapy. HIV Hotline No Original Data.
  287. Hydroxyurea marketed for sickle cell anemia. Am J Health Syst Pharm 98;55(9):875 No Original Data. [PubMed: 9588244]
  288. Hydroxyurea under study. Posit Aware 95;5 No Original Data.
  289. Hydroxyurea vs anagrelide. Pharm. J. 2005;275(7357):38 No Original Data.
  290. Hydroxyurea: what it is. New Mexico AIDS InfoNet. Newsline People AIDS Coalit N Y 98;15 No Original Data. [PubMed: 11367449]
  291. In re Cabrera. Atl Report 89;5521114–21 Not relevant to key questions.
  292. Jackson RE, Short BJ. Frequency and prognosis of coexisting sickle cell disease and acute leukemia in children. Clin Pediatr (Phila) 72;11(3):183–5. Not relevant to key questions. [PubMed: 4502362]
  293. Jacobs P, le Roux I, Jacobs L. Megakaryoblastic transformation in myeloproliferative disorders. Cancer. 84;54(2):297–302. Not relevant to key questions. [PubMed: 6586278]
  294. Jayabose S, Tugal O, Sandoval C. et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 96;129(4):559–65. Study size too small. [PubMed: 8859263]
  295. Jensen AW, Tefferi A, Arndt CAS. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. J Pediatr Hematol Oncol. 2007;29(3):156–159. Not relevant to key questions. [PubMed: 17356393]
  296. Johansson P, Ricksten A, Wasslavik C. et al. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera. Haematologica. 2004;89(10):1264–1266. Not relevant to key questions. [PubMed: 15477215]
  297. Johnson C S. An Alternative Approach To Hydroxyurea Therapy In Sickle Cell Disease. Not relevant to key questions.
  298. Johnson CS. Therapeutic manipulation of globin gene expression in the hemoglobinopathies. J NATL MED ASSOC. 86;78(7):599–600. No Original Data. [PMC free article: PMC2571390] [PubMed: 3746928]
  299. Johnson FD, Jacobs EM. Chemotherapy of metastatic malignant melanoma. Experience with 73 patients. Cancer. 71;27(6):1306–12. Study size too small, No Original Data. [PubMed: 4253429]
  300. Johnson L. Sickle cell disease patients and patient-controlled analgesia. Br J Nurs. 2003;12(3):144–53. Other, No Original Data. [PubMed: 12610369]
  301. Johnson RJ, Owen RG, Child JA. et al. Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim) Br J Haematol. 96;93(4):863–8. Not relevant to key questions, study size too small. [PubMed: 8703818]
  302. Johnson S, Kass NE, Natowicz M. Disclosure of personal medical information: differences among parents and affected adults for genetic and nongenetic conditions. Genet Test. 2005;9(3):269–80. Not relevant to key questions. [PubMed: 16225407]
  303. Jones FC, Broome ME. Focus groups with African American adolescents: enhancing recruitment and retention in intervention studies. J Pediatr Nurs. 2001;16(2):88–96. Not relevant to key questions, study size too small. [PubMed: 11326396]
  304. Jones JD, Kleiner DM. Awareness and Identification of Athletes With Sickle Cell Disorders at Historically Black Colleges and Universities. J Athl Train. 96;31(3):220–222. Not relevant to key questions. [PMC free article: PMC1318507] [PubMed: 16558402]
  305. Joyner S, Lee D, Hay P et al. Hydroxyurea-induced nail pigmentation in HIV patients. HIV Study size too small, other. [PubMed: 11737328]
  306. Jusko WJ. Pharmacodynamic principles in chemical teratology: dose-effect relationships. J Pharmacol Exp Ther. 72;183(3):469–80. Not relevant to key questions, No Original Data. [PubMed: 4636387]
  307. Kantarjian HM, Talpaz M. Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia. Blood. 98;92(8):2984–7. No Original Data. [PubMed: 9763593]
  308. Kaslow NJ, Brown F. Culturally sensitive family interventions for chronically ill youth: Sickle cell disease as an example. Fam Syst Med. 95;13(2):201–213. Not relevant to key questions.
  309. Kaslow NJ, Collins MH, Loundy MR. et al. Empirically validated family interventions for pediatric psychology: sickle cell disease as an exemplar. J Pediatr Psychol. 97;22(2):213–27. Not relevant to key questions. [PubMed: 9114644]
  310. Kaslow NJ, Collins MH, Rashid FL. et al. The efficacy of a pilot family psychoeducational intervention for pediatric Sickle Cell Disease (SCD) Fam Syst Health. 2000;18(4):381–404. Not relevant to key questions.
  311. Kato N, Kimura K, Yasukawa K. et al. Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: A case report and review of the literature. J Dermatol. 99;26(1):56–62. Not relevant to key questions. [PubMed: 10063214]
  312. Kaufman RE. Hydroxyurea: Specific therapy for sickle cell anemia? BLOOD. 92;79(10):2503–2506. No Original Data. [PubMed: 1375102]
  313. Kav S, Bostanci H. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment in Turkey. Support Care Cancer. 2006;14(12):1252–7. Not relevant to key questions. [PubMed: 16758174]
  314. Kennedy B J, Yarbro J W. Metabolic and therapeutic effects of hydroxyurea in chronic myelogenous leukemia. Trans Assoc Am Physicians 65;78391–9 Not relevant to key questions, No Original Data. [PubMed: 5217785]
  315. Kennedy BJ. Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood. 70;35(6):751–60. Not relevant to key questions. [PubMed: 5269413]
  316. Kennedy BJ. Hydroxyurea-associated leg ulceration. Ann Intern Med. 98;129(3):252. author reply 252–3 Not relevant to key questions, No Original Data. [PubMed: 9696737]
  317. King AA, Tang S, Ferguson KL. et al. An education program to increase teacher knowledge about sickle cell disease. J Sch Health. 2005;75(1):11–4. Not relevant to key questions, No Original Data. [PubMed: 15776876]
  318. Kirby B, Gibson LE, Rogers S. et al. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin Exp Dermatol. 2000;25(3):256–7. Not relevant to key questions, No Original Data. [PubMed: 10844510]
  319. Kirby B, Rogers S, Pittelkow MR. et al. Hydroxyurea-induced dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea [2] (multiple letters) J Am Acad Dermatol. 98;38(5 I):781–782. Not relevant to key questions, No Original Data. [PubMed: 9591832]
  320. Kirby B, Rogers S. Hydroxyurea-induced dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 98;38(5 Pt 1):781–2. No Original Data. [PubMed: 9591832]
  321. Kirk SA. Sickle cell disease and health education. Midwife Health Visit Community Nurse. 87;23(5):200–6. Not relevant to key questions, No Original Data. [PubMed: 3649554]
  322. Klener P, Donner L. Hydroxyurea (Biosupressin-BIOGAL) for the treatment of chronic myelogenous leukaemia. Ther Hung. 81;29(1):38–41. Study size too small. [PubMed: 6964902]
  323. Kliewer W, Lewis H. Family influences on coping processes in children and adolescents with sickle cell disease. J Pediatr Psychol. 95;20(4):511–25. Not relevant to key questions. [PubMed: 7666291]
  324. Klingebiel T, Creutzig U, Dopfer R. et al. Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia. Bone Marrow Transplant. 90;5(5):317–20. Not relevant to key questions, study size too small. [PubMed: 2190658]
  325. Kluin-Nelemans HC, Buck G, le Cessie S. et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood. 2004;103(12):4408–15. Not relevant to key questions. [PubMed: 15010373]
  326. Kluin-Nelemans JC, Delannoy A, Louwagie A. et al. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-(alpha)2b for chronic myeloid leukemia. Blood. 98;91(8):2713–2721. Not relevant to key questions. [PubMed: 9531580]
  327. Koc A, Gumruk F, Gurgey A. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol. 2003;20(6):429–34. Study size too small. [PubMed: 14631615]
  328. Kodish E, Lantos J, Siegler M. et al. Bone marrow transplantation in sickle cell disease: the trade-off between early mortality and quality of life. Clin Res. 90;38(4):694–700. Not relevant to key questions, No Original Data. [PubMed: 2276257]
  329. Koh LP, Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib [1] Int J Hematol. 2006;84(5):459–462. Not relevant to key questions. [PubMed: 17189230]
  330. Kolitz JE, Kempin SJ, Schluger A. et al. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol. 92;19(3 Suppl 9):27–33. Study size too small. [PubMed: 1641654]
  331. Konior GS, Yarbro JW. Hydroxyurea in the treatment of chronic myeloid leukemia. South Med J. 71;64(2):247–8. Study size too small, Not relevant to key questions. [PubMed: 5549316]
  332. Konotey-Ahulu FID. Opiates for sickle-cell crisis? [8] Lancet. 98;351(9113):1438. No Original Data. [PubMed: 9593444]
  333. Konotey-Ahulu FID. Sickle-cell disease and the patient [3] Lancet. 2005;365(9457):382–383. No Original Data. [PubMed: 15680445]
  334. Konotey-Ahulu FI. Management of patients with sickle-cell disease. Lancet. 72;2(7780):772. No Original Data. [PubMed: 4116192]
  335. Koontz K, Short AD, Kalinyak K. et al. A randomized, controlled pilot trial of a school intervention for children with sickle cell anemia. J Pediatr Psychol. 2004;29(1):7–17. Not relevant to key questions. [PubMed: 14747361]
  336. Koren A, Segal-Kupershmit D, Zalman L. et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr Hematol Oncol. 99;16(3):221–32. Study size too small. [PubMed: 10326220]
  337. Krakoff I H, Savel H, Murphy M L. Phase Ii Studies Of Hydroxyurea (Nsc-32065) In Adults: Clinical Evaluation. Cancer Chemother Rep 64;4053–5 Not relevant to key questions, No Original Data.
  338. Kramer KD, Nash KB. The sickle cell mutual assistance movement. J Health Soc Policy. 94;5(34):203–14. Not relevant to key questions. [PubMed: 10138759]
  339. Kreft A, Nolde C, Busche G. et al. Polycythaemia vera: Bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol. 2000;64(1):32–41. Study size too small. [PubMed: 10680703]
  340. Kuhr T, Burgstaller S, Apfelbeck U. et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML) Leuk Res. 2003;27(5):405–11. Not relevant to key questions, other. [PubMed: 12620292]
  341. Kunitz SJ. Some notes on physiologic conditions as social problems. Soc Sci Med. 74;8(4):207–11. No Original Data. [PubMed: 4837358]
  342. Kwong YL, Brandt L. Leukaemic risk in polycythaemia vera and essential thrombocytopenia [2] EUR J HAEMATOL. 96;56(12):90–92. No Original Data. [PubMed: 8600002]
  343. Kwong YL, Liang RH, Chiu EK. et al. Essential thrombocythemia: a retrospective analysis of 39 cases. Am J Hematol. 95;49(1):39–42. Study size too small, Not relevant to key questions. [PubMed: 7741136]
  344. Kwong YL. Leukaemic risk in polycythaemia vera and essential thrombocytopenia. Eur J Haematol. 96;56(12):90–2. No Original Data. [PubMed: 8600002]
  345. Labropoulos N, Manalo D, Patel NP. et al. Uncommon leg ulcers in the lower extremity. J Vasc Surg. 2007;45(3):568–573. Not relevant to key questions. [PubMed: 17257802]
  346. Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol. 2004;41(SUPPL. 6):17–22. No Original Data. [PubMed: 15534853]
  347. Landau Hurtig A, Park KB. Adjustment and coping in adolescents with sickle cell disease. Ann New York Acad Sci. 89;565(-):172–182. Not relevant to key questions. [PubMed: 2774423]
  348. Lane JC, Scott RB. Awareness of sickle cell anemia among negroes of Richmond, Va. Public Health Rep. 69;84(11):949–53. Not relevant to key questions. [PMC free article: PMC2031706] [PubMed: 4982253]
  349. Lanigan C, Justins D. Sickle cell crisis and pain management +AFs-14+AF0- ANAESTHESIA. 93;48(9):829–830. Not relevant to key questions. [PubMed: 8214516]
  350. Lanzkron S, Haywood C, Segal JB. et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006;81(12):927–32. Not relevant to key questions. [PubMed: 16924648]
  351. Laughon S K, Shinn L L, Nunley J R. Melanonychia and mucocutaneous hyperpigmentation due to hydroxyurea use in an HIV-infected patient. Int J Dermatol Not relevant to key questions, other. [PubMed: 11168664]
  352. Lawrence C, Bentley HP. Relief of sickle cell anemia pain. J Med Assoc State Ala. 80;49(9):16–8. Not relevant to key questions. [PubMed: 7373180]
  353. Layton A M, Cotterill J A. Immunological changes in hydroxyurea-induced collagen disease. Br J Dermatol Other. [PubMed: 7947215]
  354. Lazzarino M, Morra E, Brusamolino E. et al. Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia. Am J Clin Oncol. 86;9(1):45–9. Not relevant to key questions. [PubMed: 3513537]
  355. Leavell U W, Yarbro J W. Treatment of psoriasis by hydroxyurea. South Med J Not relevant to key questions, No Original Data. [PubMed: 5097801]
  356. Lee DA, Mueller BU. Long-term use of hydroxyurea for sickle cell anemia. JAMA. 2003;290(6):753–4. author reply 754 No Original Data. [PubMed: 12915425]
  357. Lee EJ, Phoenix D, Brown W. et al. Sickle cell disease: problem solving/coping methods among affected children and their non-affected siblings. J Sch Nurs. 98;14(5):24–8. Not relevant to key questions. [PubMed: 10085845]
  358. Lee EJ, Phoenix D, Jackson BS. et al. The role of family: perceptions of children with sickle cell. J Natl Black Nurses Assoc. 99;10(2):37–45. Not relevant to key questions. [PubMed: 10732595]
  359. Lee MT, Piomelli S, Granger S. et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847–52. Not relevant to key questions. [PMC free article: PMC1895848] [PubMed: 16861341]
  360. Leonardi V, Meli M, Palmeri S. Hydroxyurea as a modulator of multidrug resistance in resistant solid tumor: A pilot study. Oncol Rep. 97;4(4):723–727. Not relevant to key questions. [PubMed: 21590128]
  361. Lerner HJ, Beckloff GL, Godwin MC. Hydroxyurea (NSC-32065) intermittent therapy in malignant diseases. Cancer Chemother Rep. 69;53(6):385–95. Study size too small. [PubMed: 4915083]
  362. Lerner HJ, Beckloff GL, Godwin MC. Phase II study of hydroxyurea administered intermittently in malignant melanoma. Am Surg. 70;36(8):505–8. Study size too small. [PubMed: 5450423]
  363. Levantine A, Almeyda J. Drug reactions. XXIV. Cutaneous reactions to cytostatic agents. Br J Dermatol No Original Data. [PubMed: 4132051]
  364. Levy JC, Strong RM, Browne C. et al. An integrated system for health supervision. Pediatr Clin North Am. 74;21(2):291–305. Not relevant to key questions. [PubMed: 4837168]
  365. Lima CS, Arruda VR, Costa FF. et al. Minimal doses of hydroxyurea for sickle cell disease. Braz J Med Biol Res. 97;30(8):933–40. Study size too small. [PubMed: 9361721]
  366. Lipshutz H, Lerner HJ, Beckloff GL. Hydroxyurea in the management of head and neck cancer. II. Surgical aspects. Plast Reconstr Surg. 67;40(3):240–2. Not relevant to key questions. [PubMed: 6037153]
  367. Listernick R. An 11-year-old boy with sickle cell disease and abdominal pain. Pediatr. Ann. 2005;34(9):673+677–679 No Original Data. [PubMed: 16222944]
  368. Little JA, McGowan VR, Kato GJ. et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006;91(8):1076–83. Not relevant to key questions, study size too small. [PMC free article: PMC3522485] [PubMed: 16885048]
  369. Liu J, Al-Hothari MA, Mahboob FA. Non surgical treatment of recurrent or stuttering priapism in sickle cell children. Saudi Med J. 2003;24(10):1143–1145. No Original Data, study size too small. [PubMed: 14578990]
  370. Lofvenberg E, Wahlin A, Roos G. et al. Reversal of myelofibrosis by hydroxyurea. EUR J HAEMATOL. 90;44(1):33–38. Not relevant to key questions. [PubMed: 2307218]
  371. Lomen PL, Khilanani P, Kessel D. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816) Neoplasma. 80;27(1):101–6. Not relevant to key questions, study size too small. [PubMed: 6154898]
  372. Long DL, Pierre RV. Autosomal monosomy mosaicism in human bone marrow aspirate. Report of a case. Am J Clin Pathol. 68;50(4):482–4. Not relevant to key questions. [PubMed: 5676342]
  373. Longhurst H J, Pinching A J. Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine. BMJ Not relevant to key questions, other. [PMC free article: PMC26596] [PubMed: 11154621]
  374. Lori F, Foli A, Groff A. et al. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (‘virostatic’) mechanisms. AIDS. 2005;19(11):1173–81. Invitro only, No Original Data, other. [PubMed: 15990570]
  375. Lori F, Pollard RB, Whitman L. et al. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 2005;21(4):263–72. Not relevant to key questions, other. [PubMed: 15943568]
  376. Losada R, Bravo I, Capildeo K. et al. Is the group of older sickle cell disease patients from Trinidad and Tobago different? [3] Am J Hematol. 2006;81(3):219–220. Not relevant to key questions. [PubMed: 16493601]
  377. Losada R, Bravo I, Capildeo K. et al. Is the group of older sickle cell disease patients from Trinidad and Tobago different? Am J Hematol. 2006;81(3):219–20. Not relevant to key questions. [PubMed: 16493601]
  378. Louwagie A, Delannoy A, Kluin-Nelemans JC. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. Bone Marrow Transplant. 96;17(SUPPL. 3):S19–S20. Not relevant to key questions.
  379. Loven D, Hardoff R, Sever ZB. et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67(12):221–6. Study size too small. [PubMed: 15072471]
  380. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. The Benelux CML Study Group. Bone Marrow Transplant 96;17 Suppl 3S19–20 Not relevant to key questions. [PubMed: 8769694]
  381. Lu CM, Wang E, Lawrence HJ. Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;172(2):174–175. Not relevant to key questions. [PubMed: 17213030]
  382. Lucas GJ, Lehrnbecher W. Hydroxyurea in nasopharyngeal cancer. JAMA. 69;210(13):2397. Not relevant to key questions. [PubMed: 5395395]
  383. Luce JK. Chemotherapy of melanoma. Semin Oncol. 75;2(2):179–85. No Original Data. [PubMed: 1234375]
  384. Lusher JM, Sarnalk S. Hematology. J Am Med Assoc. 96;275(23):1814–1815. No Original Data.
  385. Lusher J, Elander J, Bevan D. et al. Analgesic addiction and pseudoaddiction in painful chronic illness. Clin J Pain. 2006;22(3):316–24. Not relevant to key questions. [PubMed: 16514333]
  386. Lutz MJ, Barakat LP, Smith-Whitley K. et al. Psychological adjustment of children with sickle cell disease: Family functioning and coping. Rehabil Psychol. 2004;49(3):224–232. Not relevant to key questions.
  387. Luzzati R, Di Perri G, Fendt D. et al. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine [11] J Antimicrob Chemother. 98;42(4):565–566. Not relevant to key questions, study size too small. [PubMed: 9818769]
  388. Luzzati R, Di Perri G, Fendt D. et al. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine. J Antimicrob Chemother. 98;42(4):565–6. Not relevant to key questions, study size too small. [PubMed: 9818769]
  389. Luzzato L. Services for people with haemoglobinopathy [20] BR MED J. 94;308(6945):1714. No Original Data. [PMC free article: PMC2540650] [PubMed: 7695685]
  390. Magee CC, Abraham K, Farrell J. et al. Renal thrombotic microangiopathy associated with interferon-alpha treatment of chronic myeloid leukemia. Am J Kidney Dis. 2000;36(1):E5. Not relevant to key questions. [PubMed: 10873904]
  391. Maggio A, Rigano P, D''Amico G. et al. Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies. Eur J Haematol. 2005;75(3):267–269. Not relevant to key questions, study size too small. [PubMed: 16104887]
  392. Makis AC, Hatzimichael EC, Kolios G. et al. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. Haematologica. 2004;89(3):360–1. Not relevant to key questions, study size too small. [PubMed: 15020278]
  393. Malhotra U, Bosch RJ, Wang R. et al. Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. AIDS Res Hum Retroviruses. 2004;20(8):807–12. Not relevant to key questions, study size too small. [PubMed: 15320983]
  394. Maloisel F, Uettwiller F, Laplace A. et al. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet. 99;113(2):172–6. Not relevant to key questions, study size too small. [PubMed: 10484986]
  395. Mammen EF. Part 2: Essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(4):305–306. No Original Data.
  396. Manley AF. Legislation and funding for sickle cell services, 1972-1982. Am J Pediatr Hematol Oncol. 84;6(1):67–71. Not relevant to key questions, No Original Data. [PubMed: 6711766]
  397. Marsh JCW, Bevan DH. Haematological care of the Jehovah''s witness patient. Br J Haematol. 2002;119(1):25–37. No Original Data. [PubMed: 12358900]
  398. Martel-Pelletier J, Pelletier JP. Degradative changes in human articular cartilage induced by chemotherapeutic agents. J RHEUMATOL. 86;13(1):164–174. Not relevant to key questions. [PubMed: 3701730]
  399. Marwick C. Sickle cell problems continue to challenge medical science, but some progress is noted. JAMA 90;263(4):490, 493 No Original Data. [PubMed: 1688460]
  400. Maserati R. Hydroxyurea in the treatment of HIV-1 infection: Toxicity and side effects. J Biol Regul Homeostatic Agents. 99;13(3):181–185. No Original Data. [PubMed: 10560753]
  401. Maunoury C, Acar P, De Montalembert M. et al. Myocardial perfusion in children with sickle cell disease. Am J Cardiol. 2003;91(3):374–376. Not relevant to key questions. [PubMed: 12565106]
  402. Maxwell K, Streetly A, Oni L. Fair shares for London. Mod Midwife. 97;7(11):15–9. Not relevant to key questions. [PubMed: 9470698]
  403. Maxwell K, Streetly A. Living with sickle cell pain. Nurs Stand. 98;13(9):33. No Original Data. [PubMed: 9923342]
  404. Mayer ML, Konrad TR, Dvorak CC. Hospital resource utilization among patients with sickle cell disease. J Health Care Poor Underserved. 2003;14(1):122–35. Not relevant to key questions. [PubMed: 12613072]
  405. McCabe ERB, Patterson PJ, Botsonis H. et al. Genetic services for underserved populations. C. Finance/insurance issues: A study of medical costs associated with selected genetic disorders in Texas. Birth Defects Orig Artic Ser. 90;26(2):132–138. Not relevant to key questions. [PubMed: 2128817]
  406. McCabe MG, Broadbent V, Williams DM. Unusual cause of extradural haemorrhage. Med Pediatr Oncol. 2001;36(6):654–656. Not relevant to key questions. [PubMed: 11344500]
  407. McClain BC, Kain ZN. Pediatric palliative care: a novel approach to children with sickle cell disease. Pediatrics. 2007;119(3):612–4. No Original Data. [PubMed: 17332215]
  408. McDonald C J. Chemotherapy of psoriasis. Int J Dermatol No Original Data.
  409. McDonald C J. The uses of systemic chemotherapeutic agents in psoriasis. Pharmacol No Original Data. [PubMed: 7033998]
  410. McMahon C, Callaghan CO, O'Brien D. et al. The increasing prevalence of childhood sickle-cell disease in Ireland. Ir J Med Sci. 2001;170(3):183–5. Not relevant to key questions. [PubMed: 12120971]
  411. McMeekin T O, Moschella S L. Iatrogenic complications of dermatologic therapy. Primum non nocere. Med Clin North Am No Original Data. [PubMed: 86664]
  412. McMullin MF, Bareford D, Campbell P. et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174–195. No Original Data. [PubMed: 16029446]
  413. McNamara JJ. Planning for the economic and career impact of a sickle cell anemia program. Health Serv Rep. 74;89(3):283–5. Not relevant to key questions, No Original Data. [PMC free article: PMC1616204] [PubMed: 4829490]
  414. Mehta J, Powles R, Singhal S. et al. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results. Leuk Lymphoma. 96;23(12):107–11. Study size too small. [PubMed: 9021692]
  415. Mehta J, Singhal S, Mehta BC. Prognosis and therapy in chronic myeloid leukaemia. J Assoc Physicians India. 92;40(2):130–1. No Original Data. [PubMed: 1629126]
  416. Merlat A, Lai JL, Sterkers Y. et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 99;13(2):250–7. Not relevant to key questions, study size too small. [PubMed: 10025899]
  417. Merz B. Promising drug combination for sickle cell anemia. JAMA. 89;261(21):3069. No Original Data. [PubMed: 2716139]
  418. Midence K, McManus C, Fuggle P. et al. Psychological adjustment and family functioning in a group of British children with sickle cell disease: preliminary empirical findings and a meta-analysis. Br J Clin Psychol. 96;35( Pt 3):439–50. Not relevant to key questions. [PubMed: 8889085]
  419. Mitka M. Seeking a way to alleviate sickle cell disease. JAMA. 2002;288(16):1970. No Original Data. [PubMed: 12387636]
  420. Moertel C G, Reitemeier R J, Hahn R G. Evaluation of hydroxyurea (NSC-32065) by parenteral infusion. Cancer Chemother Rep 65;4927–9 Not relevant to key questions.
  421. Morgan MT. Don''t blame the patients. West J Med. 99;171(56):313–4. No Original Data. [PMC free article: PMC1308743] [PubMed: 10639867]
  422. Morison WL. Anti-viral treatment of warts. Br J Dermatol. 75;92(1):97–9. Not relevant to key questions. [PubMed: 1156549]
  423. Morra E, Alimena G, Lazzarino M. et al. Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia. Eur J Cancer. 91;27(Suppl 4):S14–7. Not relevant to key questions. [PubMed: 1799466]
  424. Morris CR, Vichinsky EP, van Warmerdam J. et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25(8):629–34. Study size too small. [PubMed: 12902916]
  425. Morris K. Addressing the crisis of care for sickle-cell disease. Lancet. 99;353(9163):1504. No Original Data. [PubMed: 10232329]
  426. Moskowitz JT, Butensky E, Harmatz P. et al. Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer. 2007;48(1):64–71. Not relevant to key questions. [PubMed: 16622841]
  427. Munoz A, Bureo E, Ortega JJ. et al. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON) Haematologica. 98;83(11):981–4. Not relevant to key questions, study size too small. [PubMed: 9864916]
  428. Murphy MJ. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use. Fac Notes (New Orleans La) 98;10(2):1–2. No Original Data. [PubMed: 11365124]
  429. Murphy M L, Chaube S. Preliminary Survey Of Hydroxyurea (Nsc-32065) As A Teratogen. Cancer Chemother Rep Invitro only, other. [PubMed: 14206908]
  430. Naclerio AL, Gardner JW, Pollack MM. Socioeconomic factors and emergency pediatric ICU admissions. Ann New York Acad Sci. 99;896(-):379–382. Not relevant to key questions. [PubMed: 10681928]
  431. Nadel C, Portadin G. Sickle cell crises: psychological factors associated with onset. N Y State J Med. 77;77(7):1075–8. Not relevant to key questions. [PubMed: 267253]
  432. Nagel RL. The dilemma of marrow transplantation in sickle cell anemia. Semin Hematol. 91;28(3):233–4. Not relevant to key questions, No Original Data. [PubMed: 1887250]
  433. Nahavandi M, Wyche MQ, Perlin E. et al. Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy. Hematol. 2000;5(4):335–339. Study size too small. [PubMed: 11399633]
  434. Najean Y, Dresch C, Rain JD. Chronic myelogenous leukemia and myeloproliferative syndromes: Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. Nouv Rev Fr Hematol. 91;33(2):201–203. Not relevant to key questions. [PubMed: 1766854]
  435. Najean Y, Rain JD. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. BLOOD. 97;89(7):2319–2327. Not relevant to key questions. [PubMed: 9116275]
  436. Nand S, Messmore H, Fisher SG. et al. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 90;34(1):32–6. Study size too small. [PubMed: 2327402]
  437. Nanjangud G, Kadam PR, Saikia T. et al. Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis. Leuk Res. 94;18(5):385–92. Study size too small. [PubMed: 8182930]
  438. Napolez A. Narcotic dependency in the sickle cell population [12] Am J Emerg Med. 2001;19(4):329. No Original Data. [PubMed: 11447533]
  439. Natarajan S, Williamson D, Grey J. et al. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatolog Treat. 2001;12(1):33–6. Not relevant to key questions. [PubMed: 12171686]
  440. Nathan DG. Regulation of fetal hemoglobin synthesis in the hemoglobinopathies. Ann N Y Acad Sci. 85;445:177–87. No Original Data. [PubMed: 2409870]
  441. Neinstein Ls, Katz B. Patients with hematologic disorders need careful birth control counseling. Contracept Technol Update. 85;6(3):43–6. No Original Data. [PubMed: 12266720]
  442. Nevinny HB, Hall TC. Chemotherapy with hydroxyurea (NSC-32065) in renal cell carcinoma. J Clin Pharmacol J New Drugs. 68;8(6):352–9. Study size too small. [PubMed: 4883783]
  443. Newman EM, Carroll M, Akman SA. et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol. 97;39(3):254–8. Not relevant to key questions, study size too small. [PubMed: 8996529]
  444. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000;49(2):165–70. Study size too small. [PubMed: 11206012]
  445. Nienhuis AW, Ley TJ, Humphries RK. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe (beta)-thalassemia. Ann New York Acad Sci. 85;VOL. 445(-):198–211. Not relevant to key questions. [PubMed: 2409872]
  446. Nocentini G, Barzi A. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. Pharmacol Res Invitro only. [PubMed: 2284243]
  447. Noll RB, McKellop JM, Vannatta K. et al. Child-rearing practices of primary caregivers of children with sickle cell disease: the perspective of professionals and caregivers. J Pediatr Psychol. 98;23(2):131–40. Not relevant to key questions. [PubMed: 9585639]
  448. Noll RB, Ris MD, Davies WH. et al. Social interactions between children with cancer or sickle cell disease and their peers: teacher ratings. J Dev Behav Pediatr. 92;13(3):187–193. Not relevant to key questions. [PubMed: 1613114]
  449. Nzewi E. Malevolent ogbanje: recurrent reincarnation or sickle cell disease? Soc Sci Med. 2001;52(9):1403–16. Not relevant to key questions. [PubMed: 11286364]
  450. Ohaeri JU, Shokunbi WA, Akinlade KS. et al. The psychosocial problems of sickle cell disease sufferers and their methods of coping. Soc Sci Med. 95;40(7):955–60. Not relevant to key questions. [PubMed: 7792634]
  451. Ohashi N, Yonemura K, Sugiura T. et al. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis. 2003;41(3):E10. Not relevant to key questions. [PubMed: 12613003]
  452. Okpala I, Daniel Y, Haynes R. et al. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol. 2002;69(3):135–44. Study size too small. [PubMed: 12406006]
  453. Oliver TG, Glenn L, Anthony JL. et al. The establishment of a sickle cell program in the college and community health setting. J Am Coll Health. 86;34(6):290–1. Not relevant to key questions, No Original Data. [PubMed: 3745696]
  454. Olshaker JS, Barish RA, Naradzay JFX. et al. Prescription noncompliance: Contribution to Emergency Department visits and cost. J Emerg Med. 99;17(5):909–912. Study size too small. [PubMed: 10499716]
  455. Olson V, Coyne P, Smith V. et al. Critical pathway improves outcomes for patients with sickle-cell disease. Oncol Nurs Forum. 97;24(10):1682. Not relevant to key questions, other. [PubMed: 9399262]
  456. Olujohungbe A, Cinkotai KI, Yardumian A. Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results. BMJ. 98;316(7146):1689. No Original Data, Not relevant to key questions. [PMC free article: PMC1113271] [PubMed: 9614013]
  457. O''Neil JA. Sharing care, grief, and next time. J Pediatr Oncol Nurs. 95;12(3):146. No Original Data. [PubMed: 7646836]
  458. Orringer E. Efficacy Of Hydroxyurea As A Prophylactic Therapy For Sickle Cell. Not relevant to key questions.
  459. Orringer E. Safety And Efficacy Of Hydroxyurea As A Prophylactic Therapy For Sickle Cell. Not relevant to key questions.
  460. Othieno-Abinya NA, Nyabola LO, Kiarie GW. et al. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. East Afr Med J. 2002;79(11):593–7. Not relevant to key questions, other. [PubMed: 12630493]
  461. Oyedeji GA. The effects of sickle cell disease on the families of affected children. Cent Afr J Med. 95;41(10):333–4. Not relevant to key questions. [PubMed: 8556783]
  462. Palejwala AA, Hong LY, King D. Managing patients with an absent or dysfunctional spleen. Under half of doctors know that antibiotic prophylaxis should be life long. BMJ. 96;312(7042):1360. author reply 1361 Not relevant to key questions, No Original Data. [PMC free article: PMC2351005] [PubMed: 8646069]
  463. Palermo TM, Schwartz L, Drotar D. et al. Parental report of health-related quality of life in children with sickle cell disease. J Behav Med. 2002;25(3):269–83. Not relevant to key questions. [PubMed: 12055777]
  464. Papassotiriou I, Voskaridou E, Stamoulakatou A. et al. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J. 2000;1(5):295–300. Study size too small. [PubMed: 11920206]
  465. Papineschi F, Carulli G, Petrini M. Plicamycin-hydroxyurea association in chronic granulocytic leukemia and multidrug resistance. Haematologica. 91;76(4):349. Not relevant to key questions. [PubMed: 1686602]
  466. Parker R, Lanvin D, Gilks B. et al. Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis. Gynecol Oncol. 2001;82(2):395–9. Not relevant to key questions. [PubMed: 11531303]
  467. Parodi A, Alibrandi B, Rebora A. Dermatomyositis-like cutaneous lesions due to hydroxyurea. G ITAL Dermatol Venereol. 92;127(78):361–362. Not relevant to key questions.
  468. Parra Ruiz J, Callejas Rubio JL, Munoz Medina L. et al. Dermatitis in a patient with chronic myeloid leukemia. Rev Clin Esp. 2002;202(4):235–236. Other. [PubMed: 12003736]
  469. Passamonti F, Pietra D, Rumi E. et al. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia +AFs-9+AF0- Leukemia. 2005;19(5):888–889. Not relevant to key questions. [PubMed: 15744342]
  470. Patel AB, Athavale AM. Sickle cell disease in central India. Indian J Pediatr. 2004;71(9):789–93. Not relevant to key questions. [PubMed: 15448384]
  471. Patel AB, Pathan HG. Quality of life in children with sickle cell hemoglobinopathy. Indian J Pediatr. 2005;72(7):567–71. Not relevant to key questions. [PubMed: 16077239]
  472. Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas. Lancet 95;346(8987):1408–11 Study size too small. [PubMed: 7475827]
  473. Paton NI, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6(1):13–20. Not relevant to key questions. [PubMed: 15670247]
  474. Pavlidis NA. Cancer and pregnancy. Ann Oncol. 2000;11(SUPPL. 3):247–253. No Original Data. [PubMed: 11079149]
  475. Paydas S, Zorludemir S, Sahin B. Vasculitis and leukemia. Leuk Lymphoma. 2000;40(12):105–12. Not relevant to key questions. [PubMed: 11426610]
  476. Pearson HA, O''Brien RT, McIntosh S. et al. Routine screening of umbilical cord blood for sickle cell diseases. JAMA. 74;227(4):420–1. Not relevant to key questions. [PubMed: 4859678]
  477. Pearson TC, Green AR, Reilly JT. et al. Leukemic transformation in polycythemia vera [1] (multiple letters) Blood. 98;92(5):1837–1338. No Original Data. [PubMed: 9716616]
  478. Pearson TC, Green AR, Reilly JT. et al. Leukemic transformation in polycythemia Vera. MPD(UK) Study Group. Blood. 98;92(5):1837–8. No Original Data. [PubMed: 9716616]
  479. Pegelow CH, Armstrong FD, Light S. et al. Experience with the use of prophylactic penicillin in children with sickle cell anemia. J Pediatr. 91;118(5):736–8. Not relevant to key questions. [PubMed: 2019928]
  480. Perry DF, Ireys HT. Maternal perceptions of pediatric providers for children with chronic illnesses. Matern Child Health J. 2001;5(1):15–20. Not relevant to key questions. [PubMed: 11341716]
  481. Perry V. Myths and facts...about sickle-cell disease. Nursing. 2005;35(12):27. No Original Data. [PubMed: 16331199]
  482. Perutz MF, Rosa J, Schechter A. Therapeutic agents for sickle cell disease. Nature. 78;275(5679):369–70. No Original Data. [PubMed: 692720]
  483. Petrakis NL. Sickle-cell disease. Lancet. 74;2(7893):1368–9. No Original Data. [PubMed: 4143327]
  484. Petti MC, Tafuri A, Latagliata R. et al. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Ann Hematol. 2003;82(8):476–80. Study size too small. [PubMed: 12835916]
  485. Piver MS. Standard administration of hydroxyurea recommended. Am J Obstet Gynecol. 89;161(5):1425–6. Not relevant to key questions, No Original Data. [PubMed: 2686460]
  486. Platt A, Beasley J, Miller G. et al. Managing sickle-cell pain... and all that goes with it: learn the complex problems this disease triggers and how to support your patient during a crisis. Nursing. 2002;32(12):32hn1. No Original Data.
  487. Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia - The dilemma of choice. NEW ENGL J MED. 96;335(6):426–428. No Original Data. [PubMed: 8663876]
  488. Platt O S, Orkin S H, Dover G et al. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Trans Assoc Am Physicians 84;97268–74 No Original Data. [PubMed: 6085528]
  489. Platt OS. Sickle cell paths converge on hydroxyurea. Nat Med. 95;1(4):307–8. No Original Data. [PubMed: 7585059]
  490. Podos SM, Canellos GP. Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy. Am J Ophthalmol. 69;68(3):500–4. Study size too small, Not relevant to key questions. [PubMed: 5257915]
  491. Porter LS, Gil KM, Sedway JA. et al. Pain and stress in sickle cell disease: An analysis of daily pain records. Int J Behav Med. 98;5(3):185–203. Not relevant to key questions. [PubMed: 16250701]
  492. Potrykus C. Sickle cell. Black counsellors under pressure. Health Visit. 93;66(7):239–40. No Original Data. [PubMed: 8365892]
  493. Powars DR. Hydroxyurea in very young children with sickle cell anemia is not a cure-all. J Pediatr. 2001;139(6):763–4. No Original Data. [PubMed: 11743496]
  494. Powers SW, Mitchell MJ, Graumlich SE. et al. Longitudinal assessment of pain, coping, and daily functioning in children with sickle cell disease receiving pain management skills training. J Clin Psychol Med Settings. 2002;9(2):109–119. Not relevant to key questions.
  495. Prasad R, Hasan S, Castro O. et al. Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci. 2003;325(3):107–9. Not relevant to key questions. [PubMed: 12640284]
  496. Price CL, Boyd JH, Watkins AR. et al. Mailing of a sickle cell disease educational packet increases blood donors within an African American community. Transfusion. 2006;46(8):1388–93. Not relevant to key questions. [PubMed: 16934076]
  497. Prielipp RC, Butterworth JF. Clinical guidelines. Anesth Analg. 2000;90(2):503. Not relevant to key questions, No Original Data. [PubMed: 10648357]
  498. Psychosocial aspects of sickle cell disease: past, present, and future directions of research. J Health Soc Policy 94;5(3–4):1–269 No Original Data. [PubMed: 10138754]
  499. Puffer E, Schatz J, Roberts CW. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease. Child Neuropsychol. 2007;13(2):142–54. Study size too small. [PubMed: 17364571]
  500. Quaglino D, Torelli U, Emilia G. A preliminary clinical evaluation of the therapeutic effects of hydroxyurea in patients with myelogenous leukaemia. Eur J Cancer. 66;2(1):69–74. Study size too small. [PubMed: 5227599]
  501. Rahimi-Levene N, Hagay Z, Elchalal U. et al. Essential thrombocythemia and pregnancy +AFs-4+AF0- AM J HEMATOL. 94;45(4):348–349. Not relevant to key questions, No Original Data. [PubMed: 8192818]
  502. Randall VR. Slavery, segregation and racism: trusting the health care system ain''t always easy! An African American perspective on bioethics. St Louis Univ Public Law Rev. 96;15(2):191–235. No Original Data. [PubMed: 11656870]
  503. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma. 2000;37(34):379–85. Not relevant to key questions. [PubMed: 10752989]
  504. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents [2] Haematologica. 99;84(11):1049–1050. Study size too small, other. [PubMed: 10553169]
  505. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents. Haematologica. 99;84(11):1049–50. No Original Data. [PubMed: 10553169]
  506. Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia [1] Br J Haematol. 2002;116(4):923. No Original Data. [PubMed: 11886403]
  507. Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia. Br J Haematol. 2002;116(4):923–4. No Original Data. [PubMed: 11886403]
  508. Recent prescription approvals, changes, and recalls. Oncol. Spectr. 2001;2(8):576 No Original Data, other.
  509. Reichman R C. Actg A5025: S&E Of Hydroxyurea In Subjects On Potent Antiretroviral T. Not relevant to key questions.
  510. Reynolds N, Smith CH. Hydroxyurea in psoriasis [1] (multiple letters) Clin Exp Dermatol. 99;24(6):496–497. No Original Data. [PubMed: 10681171]
  511. Rivers R, Williamson N. Sickle cell anemia: complex disease, nursing challenge (continuing education credit) RN. 90;53(6):24–9. No Original Data. [PubMed: 2363002]
  512. Roberts L. One worked; the other didn''t. Science. 90;247(4938):18. Not relevant to key questions, No Original Data. [PubMed: 2294586]
  513. Robertson LE, Estey E, Kantarjian H. et al. Therapy-related leukemia and myelodyspiastic syndrome in chronic lymphocytic leukemia. LEUKEMIA. 94;8(12):2047–2051. Not relevant to key questions. [PubMed: 7807993]
  514. Rochester-Peart C. Specialist nurse support for clients with blood disorders. Nurs Times. 97;93(41):52–4. Not relevant to key questions, No Original Data. [PubMed: 9370693]
  515. Rodgers GP, Dover GJ, Noguchi CT. et al. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 90;322(15):1037–45. Study size too small. [PubMed: 1690857]
  516. Rodgers GP, Dover GJ, Noguchi CT. et al. Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience. Prog Clin Biol Res. 89;316B:281–93. Study size too small. [PubMed: 2482498]
  517. Rodgers GP. Hydroxyurea and new agents for the treatment of sickle cell disease. Clin Adv Hematol Oncol. 2004;2(11):713–5. No Original Data. [PubMed: 16163257]
  518. Rodgers GP. Recent approaches to the treatment of sickle cell anemia. JAMA. 91;265(16):2097–101. Study size too small, No Original Data. [PubMed: 1707463]
  519. Rodgers GP. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Semin Oncol. 92;19(3 Suppl 9):67–73. Study size too small. [PubMed: 1379375]
  520. Rodriguez G. Phase I-Ii Trial Of Hydroxyurea In Treatment Of Squamous Carcinoma. Not relevant to key questions.
  521. Rodriguez-Gomez F, Cuevas O, Anguita J et al. Clinical microbiological case: Penile ulcer and lung infiltrates in a leukemic patient. Clin. Microbiol. Infect. 2001;7(12):695–696+713 Not relevant to key questions. [PubMed: 11843913]
  522. Rogers ZR, Buchanan GR. Expanding the role of hydroxyurea in children with sickle cell disease. J Pediatr. 2004;145(3):287–8. No Original Data. [PubMed: 15343174]
  523. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol. 97;34(3 Suppl 3):42–7. Study size too small. [PubMed: 9317200]
  524. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156–8. Study size too small. [PubMed: 11922703]
  525. Ruiz-Genao DP, Sanz-Sachez T, Bartolome-Gonzalez B. et al. Dermatomyositis-like reaction induced by chemotherapeutical agents. Int J Dermatol. 2002;41(12):885–887. Not relevant to key questions. [PubMed: 12492978]
  526. Rustin GJS, Rustin FP, Dent J. Second tumour incidence not increased following cytotoxic chemotherapy for gestational trophoblastic tumours. PROC AM SOC CLIN ONCOL. 82;Vol. 1(-):C–405. Not relevant to key questions, other.
  527. Rutkow IM, Lipton JM. Some negative aspects of sickle cell anemia screening programs (negative aspects of sickle cell screening) Conn Med. 74;38(5):257–62. Not relevant to key questions. [PubMed: 4831104]
  528. Rutkow IM, Lipton JM. Some negative aspects of state health departments'' policies related to screening for sickle cell anemia. Am J Public Health. 74;64(3):217–21. Not relevant to key questions. [PMC free article: PMC1775418] [PubMed: 4811763]
  529. Sadovsky R. Hydroxyurea in children with sickle cell disease. Am Fam Phys. 97;55(3):963–964. No Original Data.
  530. Saleh AW, Velvis HJ, Gu LH. et al. Hydroxyurea therapy in sickle cell anemia patients in Curacao, The Netherlands Antilles. Acta Haematol. 97;98(3):125–9. Study size too small, other. [PubMed: 9352741]
  531. Santiago LG. More information on hydroxyurea. GMHC Treat Issues. 96;10(8):10. No Original Data. [PubMed: 11363717]
  532. Santiago L. Hydroxyurea continues to show promise. GMHC Treat Issues. 96;10(2):9–11. No Original Data. [PubMed: 11363387]
  533. Sauer GC. Combined methotrexate and hydroxyurea therapy for psoriasis. Arch Dermatol. 73;107(3):369–370. Not relevant to key questions. [PubMed: 4692125]
  534. Savitt TL. The invisible malady: sickle cell anemia in America, 1910-1970. J Natl Med Assoc. 81;73(8):739–46. No Original Data. [PMC free article: PMC2552684] [PubMed: 7021863]
  535. Schechter AN, Rodgers GP, Adams-Graves P. et al. Hydroxyurea in sickle cell disease [4] New Engl J Med. 96;334(5):333–334. No Original Data. [PubMed: 8532042]
  536. Schechter AN, Rodgers GP, Strasser BJ. Sickle cell anemia therapy: Progress since Pauling [3] (multiple letters) Science. 2000;287(5453):592–593. No Original Data. [PubMed: 10691539]
  537. Schechter AN, Rodgers GP. Hydroxyurea in sickle cell disease. N Engl J Med. 96;334(5):333. No Original Data. [PubMed: 8532042]
  538. Schechter AN, Rodgers GP. Hydroxyurea in sickle cell disease. N Engl J Med. 96;334(5):333. Not relevant to key questions. [PubMed: 8532042]
  539. Schechter AN, Rodgers GP. Sickle cell anemia—basic research reaches the clinic. N Engl J Med. 95;332(20):1372–4. No Original Data. [PubMed: 7536300]
  540. Schechter AN. Sickle cell disease expenditures and outcomes. Public Health Rep. 97;112(1):38–39. No Original Data. [PMC free article: PMC1381836] [PubMed: 9018286]
  541. Scheer AC, Wilson RF. Cancer of the lung and its response to non-surgical treatment. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 75;83(1):1–6. Not relevant to key questions, study size too small. [PubMed: 49984]
  542. Schmugge M, Frischknecht H, Yonekawa Y. et al. Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery. Blood. 2001;97(7):2165–7. Study size too small. [PubMed: 11264186]
  543. Schrag D, Xu F, Hanger M. et al. Fragmentation of care for frequently hospitalized urban residents. Med Care. 2006;44(6):560–7. Not relevant to key questions. [PubMed: 16708005]
  544. Schreibman SM, Gee TS, Grabstald H. Management of priapism in patients with chronic granulocytic leukemia. J Urol. 74;111(6):786–8. Not relevant to key questions. [PubMed: 4524674]
  545. Schrell UM, Rittig MG, Koch U. et al. Hydroxyurea for treatment of unresectable meningiomas. Lancet. 96;348(9031):888–9. Study size too small. [PubMed: 8826822]
  546. Schwarzenberg L, Mathe G, Pouillart P. et al. Chemotherapy with hydroxyurea, leucopheresis and splenectomy in the treatment of chronic myeloid leukemia at the problastic phase. Haematologica. 72;57(11):601–11. Not relevant to key questions. [PubMed: 4200296]
  547. Schwarzenberg L, Mathe G, Pouillart P. et al. Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase. Br Med J. 73;1(5855):700–3. Not relevant to key questions. [PMC free article: PMC1588829] [PubMed: 4512003]
  548. Schwerner H, Mellody T, Goldstein AB. et al. Evaluating the impact of a disease management program for chronic complex conditions at two large northeast health plans using a control group methodology. Dis Manage. 2006;9(1):34–44. Not relevant to key questions. [PubMed: 16466340]
  549. Scott J P. Hydroxyurea On Adhesion Of Sickle Cells To Vascular Endothelium. Not relevant to key questions.
  550. Scott RB. Health care priority and sickle cell anemia. JAMA. 70;214(4):731–4. Not relevant to key questions, No Original Data. [PubMed: 5536114]
  551. Scott RB. Sickle-cell anemia—high prevalence and low priority. N Engl J Med. 70;282(3):164–5. No Original Data. [PubMed: 5409542]
  552. Secundy MG. Psychosocial issues: Unanswered questions in the use of bone marrow transplantation for treatment of hemoglobinopathies. AM J PEDIATR HEMATOL ONCOL. 94;16(1):76–79. No Original Data. [PubMed: 8311176]
  553. Selby R, Nisbet-Brown E, Basran RK. et al. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease [4] BLOOD. 97;90(2):891–893. Not relevant to key questions. [PubMed: 9226193]
  554. Selby R, Nisbet-Brown E, Basran RK. et al. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood. 97;90(2):891–3. Not relevant to key questions. [PubMed: 9226193]
  555. Selleri C, Alfinito F, Del Vecchio L. et al. Cytoplasmic GpIIb-IIIa and cytokine secretion by blasts in a case of megakaryoblastic transformation of essential thrombocythemia. Leuk Lymphoma. 93;10(6):497–500. Not relevant to key questions. [PubMed: 8401187]
  556. Serjeant BE, Forbes M, Williams LL. et al. Screening cord bloods for detection of sickle cell disease in Jamaica. Clin Chem. 74;20(6):666–9. Not relevant to key questions. [PubMed: 4830170]
  557. Serjeant GR, Hutson C. Patterns of attendance at Jamaican sickle cell clinics 1952 to 1981. Trans R Soc Trop Med Hyg. 84;78(5):648–52. Not relevant to key questions. [PubMed: 6506153]
  558. Serjeant GR. The case for dedicated sickle cell centres. Indian J Hum Genet. 2006;12(3):148–151. No Original Data.
  559. Sharpe JN, Brown RT, Thompson NJ. et al. Predictors of coping with pain in mothers and their children with sickle cell syndrome. J Am Acad Child Adolesc Psychiatry. 94;33(9):1246–55. Not relevant to key questions. [PubMed: 7995790]
  560. Shatin D, Levin R, Ireys HT. et al. Health care utilization by children with chronic illnesses: a comparison of medicaid and employer-insured managed care. Pediatrics. 98;102(4):E44. Not relevant to key questions, study size too small. [PubMed: 9755281]
  561. Shepherd PC, Richards SM, Allan NC. Progress with interferon in CML—results of the MRC UK CML III study. Bone Marrow Transplant. 96;17(Suppl 3):S15–8. Not relevant to key questions. [PubMed: 8769693]
  562. Sherman D S, Fish D N. Hydroxyurea in the treatment of HIV infection. AIDS Reader 99;9(1):18–19+23 No Original Data. [PubMed: 12728878]
  563. Shilalukey K, Kaufman M, Bradley S. et al. Counseling sexually active teenagers treated with potential human teratogens. J Adolesc Health. 97;21(3):143–6. Not relevant to key questions. [PubMed: 9283934]
  564. Shullenberger CC. Phase Ii Studies Of Hydroxyurea (Nsc-32065) In Adults: Leukemia. Cancer Chemother Rep. 64;40:49–50. Study size too small. [PubMed: 14206918]
  565. Shuster J. Hydroxyurea and hepatitis. Nursing No Original Data. [PubMed: 10855204]
  566. Shuster J. Shock-like sensations associated with antidepressant withdrawal; Acute tumor lysis syndrome caused by hydroxyurea; Zolpidem-induced visual hallucinations; Tooth discoloration with linezolid; Sleepwalking caused by SSRI; ADR-related reports from the Archives of Internal Medicine. Hosp Pharm. 2003;38(7):631–633. No Original Data.
  567. Silbergleit R, Jancis MO, McNamara RM. Management of sickle cell pain crisis in the emergency department at teaching hospitals. J Emerg Med. 99;17(4):625–30. Not relevant to key questions. [PubMed: 10431951]
  568. Silver RT. Hydroxyurea and sickle cell crisis. N Engl J Med. 95;333(15):1008–9. No Original Data. [PubMed: 7666903]
  569. Simonelli C, Comar M, Zanussi S et al. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection. AIDS Study size too small. [PubMed: 9256953]
  570. Simonelli C, Comar M, Zanussi S. et al. No therapeutic advantage from didanosine (ddl) and hydroxyurea versus ddl alone in patients with HIV infection [6] AIDS. 97;11(10):1299–1300. Study size too small. [PubMed: 9256953]
  571. Simonsson B, Oberg G, Bjoreman M. et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Leuk Lymphoma. 92;7(Suppl5):5–7. Not relevant to key questions. [PubMed: 1283548]
  572. Simonsson B, Oberg G, Killander A. et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Swedish CML-group. Bone Marrow Transplant. 94;14(Suppl 3):S55–6. Not relevant to key questions. [PubMed: 7535154]
  573. Smith DC, Vaughan WP, Gwilt PR. et al. A phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother Pharmacol. 93;33(2):139–43. Not relevant to key questions. [PubMed: 8261572]
  574. Smith HD, McIntire MS, Grant RS. Health for the public: sickle cell program. Nebr Med J. 74;59(3):68–72. Not relevant to key questions, No Original Data. [PubMed: 4816709]
  575. Smith JP, Rutledge F, Burns BC. et al. Systemic chemotherapy for carcinoma of the cervix. Am J Obstet Gynecol. 67;97(6):800–7. Not relevant to key questions, study size too small. [PubMed: 4960089]
  576. Smith LA, Wise PH, Wampler NS. Knowledge of welfare reform program provisions among families of children with chronic conditions. Am J Public Health. 2002;92(2):228–30. Not relevant to key questions. [PMC free article: PMC1447047] [PubMed: 11818296]
  577. Smith WR, Bovbjerg VE, Penberthy LT. et al. Understanding pain and improving management of sickle cell disease: the PiSCES study. J Natl Med Assoc. 2005;97(2):183–93. Not relevant to key questions. [PMC free article: PMC2568749] [PubMed: 15712781]
  578. Smith W. Multicenter Study Of Hydroxyurea 5 Years Follow-Up Study. Not relevant to key questions.
  579. Smith-Wynter LO. Research study. The feasibility of nursing patients with sickle cell crisis at home. British Journal of Community Nursing. 99;4(10):531. Not relevant to key questions.
  580. Snyder AB, Barone JG, DiGiacomo JC. et al. Postoperative pulmonary leukostasis. Crit Care Med. 90;18(1):116–7. Not relevant to key questions. [PubMed: 2403504]
  581. Solimando DA. Hydroxyurea and pentostatin. Hosp Pharm. 98;33(6):629–635. No Original Data.
  582. Somlo P, Revesz T. Chemotherapy-induced fatal pulmonary fibrosis. NEOPLASMA. 84;31(6):739–744. Not relevant to key questions. [PubMed: 6521801]
  583. Souza R, Jardim C, Carvalho C. The need for national registries in rare diseases. Am J Respir Crit Care Med. 2006;174(2):228. author reply 228 No Original Data. [PubMed: 16822934]
  584. Sox C. Health supervision for children with sickle cell disease. Pediatrics. 2003;111(3):710–1. author reply 710–1 No Original Data. [PubMed: 12612266]
  585. Spell DW, Feldman L, Allen S. et al. Long-term Use of Hydroxyurea for Sickle Cell Anemia [2] (multiple letters) J Am Med Assoc. 2003;290(6):752–754. No Original Data. [PubMed: 12915422]
  586. Spell DW, Feldman L, Allen S. et al. Long-term use of hydroxyurea for sickle cell anemia... Steinberg MH, Barton F, Castro O et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003-;290(6):752. No Original Data. [PubMed: 12672732]
  587. Spell DW. Long-term use of hydroxyurea for sickle cell anemia. JAMA. 2003;290(6):752. author reply 754 No Original Data. [PubMed: 12915422]
  588. Spier S, Solomon L M, Esterly N B et al. Hydroxyurea and macrocytosis. Br J Dermatol Not relevant to key questions, study size too small.
  589. Squibb hydroxyurea (Hydrea). Clin Pharmacol Ther 69;10(1):142–6 No Original Data, Not relevant to key questions.
  590. Stagno F, Guglielmo P, Consoli U. et al. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor [2] Blood. 99;94(4):1479–1480. Not relevant to key questions. [PubMed: 10484634]
  591. Stavroyianni N, Stamatopoulos K, Viniou N. et al. Autoimmune hemolytic anemia during (alpha)-interferon treatment in a patient with chronic myelogenous leukemia. Leuk Res. 2001;25(12):1097–1098. Not relevant to key questions, No Original Data. [PubMed: 11684283]
  592. Steensma D P, Harrison C N, Tefferi A. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Leuk Lymphoma Not relevant to key questions. [PubMed: 11911405]
  593. Steinberg MH. Pneumococcus and sickle cell disease: The beginning of the end? Clin Infect Dis. 2007;44(11):1434–1435. No Original Data. [PubMed: 17479938]
  594. Stolbach LL, Begg CB, Hall T. et al. Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep. 81;65(78):689–92. Study size too small. [PubMed: 6454485]
  595. Strauss RG. Sickle cell patients deserve controlled recommendations. Transfusion. 2002;42(5):658–9. author reply 659–60 No Original Data. [PubMed: 12084176]
  596. Streetly A, Dick M, Layton M. Sickle cell disease: the case for coordinated information. BMJ. 93;306(6891):1491–2. No Original Data. [PMC free article: PMC1677965] [PubMed: 8518672]
  597. Stuart A, Jones SM, Walker LJ. Insights into elevated distortion product otoacoustic emissions in sickle cell disease: comparisons of hydroxyurea-treated and non-treated young children. Hear Res. 2006;212(12):83–9. Not relevant to key questions, study size too small. [PubMed: 16364581]
  598. Sualdea Montes M, Pedraza Cezon L, Martinez Nieto C et al. Compassionate use of hydroxyurea in the treatment of meningioma. Other.
  599. Suttorp M, Rister M, Schmitz N. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol. 94;22(5):358–9. Study size too small, No Original Data. [PubMed: 8127262]
  600. Swaim MW, Agarwal S, Rosse WF. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med. 2000;133(9):750–1. Study size too small. [PubMed: 11074924]
  601. Taking management of sickle cell disease to a new level. Dis Manag Advis 2001;7(1):1–5 No Original Data. [PubMed: 11214995]
  602. Tavakkoli F, Nahavandi M, Wyche MQ. et al. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clin Ther. 2005;27(7):1083–8. Study size too small. [PubMed: 16154487]
  603. Taveira LM, Goncalves C, Paiva A. et al. Efficacy of hydroxyurea in the treatment of a patient with erythrodermic psoriasis and chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol. 97;9(3):266–268. Not relevant to key questions.
  604. Tefferi A, Fenaux P, Preudhomme C. et al. Is hydroxyurea leukemogenic in essential thrombocythemia? [5] (multiple letters) Blood. 98;92(4):1459–1461. No Original Data. [PubMed: 9694740]
  605. Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia? Blood. 98;92(4):1459–60. author reply 1460–1 No Original Data. [PubMed: 9694740]
  606. Tefferi A. Pregnancy and thrombocythemia +AFs-5+AF0- Am J Hematol. 98;57(2):181–182. No Original Data. [PubMed: 9462557]
  607. Telen MJ, Harris G, Whitworth E. Caring for patients with sickle cell disease in North Carolina. N C Med J. 99;60(1):14–7. Not relevant to key questions, No Original Data. [PubMed: 9951281]
  608. Telfair J, Gardner MM. Adolescents with sickle cell disease: determinants of support group attendance and satisfaction. Health Soc Work. 2000;25(1):43–50. Not relevant to key questions. [PubMed: 10689602]
  609. Teo RYL, Tan E. A case of hydroxyurea-induced transverse melanonychia. Int J Dermatol. 2006;45(11):1329–1330. Not relevant to key questions. [PubMed: 17076717]
  610. Terrin M L. Multicenter Study Of Hydroxyurea Follow-Up. Not relevant to key questions.
  611. Tessier J, Emmons W, Newton J. et al. Age and hydroxyurea increase the risk of drug-associated peripheral neuropathy in HIV-infected patients. Infect Dis Clin Pract. 2002;11(5):276–278. Other.
  612. Thiele J, Kvasnicka HM, Ollig S. et al. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: A comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol. 2005;20(4):1071–1076. Invitro only, study size too small. [PubMed: 16136489]
  613. Thomas VJ, Cohn T. Communication skills and cultural awareness courses for healthcare professionals who care for patients with sickle cell disease. J Adv Nurs. 2006;53(4):480–8. Not relevant to key questions. [PubMed: 16448491]
  614. Thomas VJ, Dixon AL, Milligan P. Cognitive-behaviour therapy for the management of sickle cell disease pain: An evaluation of a community-based intervention. Br J Health Psychol. 99;4(3):209–229. Not relevant to key questions.
  615. Thomas VJ, Gruen R, Shu S. Cognitive-behavioural therapy for the management of sickle cell disease pain: identification and assessment of costs. Ethn Health. 2001;6(1):59–67. Not relevant to key questions. [PubMed: 11388088]
  616. Thomas V. Cognitive behavioural therapy in pain management for sickle cell disease. Int J Palliat Nurs. 2000;6(9):434–42. Not relevant to key questions. [PubMed: 12388895]
  617. Thompson RJ, Gil KM, Burbach DJ. et al. Role of child and maternal processes in the psychological adjustment of children with sickle cell disease. J CONSULT CLIN PSYCHOL. 93;61(3):468–474. Not relevant to key questions. [PubMed: 8326049]
  618. Thompson RJ, Gil KM, Keith BR. et al. Psychological adjustment of children with sickle cell disease: stability and change over a 10-month period. J Consult Clin Psychol. 94;62(4):856–6. Not relevant to key questions. [PubMed: 7962891]
  619. Todd KH, Green C, Bonham VL. et al. Sickle Cell Disease Related Pain: Crisis and Conflict. J Pain. 2006;7(7):453–458. No Original Data. [PubMed: 16814684]
  620. Torres G. Hydroxyurea, a potential new anti-HIV agent. GMHC Treat Issues. 95;9(1):7–9. No Original Data. [PubMed: 11367381]
  621. Torrey E, Simpson K, Wilbur S. et al. Malignant mastocytosis with circulating mast cells. Am J Hematol. 90;34(4):283–286. Not relevant to key questions. [PubMed: 2114786]
  622. Treatment of Ph-positive chronic myeloid leukemia with alpha-interferon (ROFERON-A). The Italian Cooperative Study Group experience. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Leuk Lymphoma 93;11 Suppl 1153–7 Not relevant to key questions. [PubMed: 8251889]
  623. Triadou P, Maier-Redelsperger M, Krishnamoorty R. et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol. 94;36(5):367–72. Not relevant to key questions, other. [PubMed: 7534399]
  624. Tubiana M, Frindel E, Vassort F. Critical survey of experimental data on in vivo synchronization by hydroxyurea. Recent Results Cancer Res 75;(52):187–205 Not relevant to key questions. [PubMed: 1235000]
  625. Tunde-Ayinmode MF, Adelekan ML. Psychosocial impact of sickle cell disease in children seen at University of Ilorin Teaching Hospital, Ilorin, Nigeria. East Afr Med J. 2005;82(2):73–8. Not relevant to key questions. [PubMed: 16122095]
  626. Tura S, Baccarani M, Zuffa E. et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. NEW ENGL J MED. 94;330(12):820–825. Not relevant to key questions. [PubMed: 8114834]
  627. Tura S, Baccarani M. Alpha-interferon in the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 95;85(10):2999–3002. Not relevant to key questions, No Original Data. [PubMed: 7742563]
  628. Uozumi K, Ohno N, Shimotakahara S. et al. Trisomy 8 in essential thrombocythemia in leukemic transformation. Cancer Genet Cytogenet. 2000;116(1):84–86. Not relevant to key questions. [PubMed: 10616540]
  629. Use of penicillin prophylaxis in sickle cell disease. AM. FAM. PHYS. 96;53(5):1828–1829 No Original Data.
  630. Van Genderen PJJ, Michiels JJ, Ring T. et al. Hydroxyurea in essential thrombocytosis [6] NEW ENGL J MED. 95;333(12):802–803. No Original Data. [PubMed: 7643898]
  631. Van Genderen PJJ, Michiels JJ, Ring T. et al. Hydroxyurea in essential thrombocytosis [6] NEW ENGL J MED. 95;333(12):802–803. Not relevant to key questions. [PubMed: 7643898]
  632. Varma S, Lanigan SW. Leg ulceration with associated thrombocytosis: Healing of ulceration associated with treatment of the raised platelet count [16] Br J Dermatol. 99;140(1):188–189. No Original Data. [PubMed: 10215806]
  633. Varma S, Lanigan SW. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br J Dermatol. 99;140(1):188–9. No Original Data. [PubMed: 10215806]
  634. Vassallo C, Brazzelli V, Ardigo M. et al. Nails changes in once-hematologic patients [12] Haematologica. 2001;86(3):334–336. No Original Data. [PubMed: 11255290]
  635. Vavasseur JW. Psychosocial aspects of chronic disease: cultural and ethnic implications. Birth Defects Orig Artic Ser. 87;23(6):144–153. No Original Data. [PubMed: 3435753]
  636. Vavasseur J. A comprehensive program for meeting psychosocial needs of sickle cell anemia patients. J Natl Med Assoc. 77;69(5):335–9. Not relevant to key questions, No Original Data. [PMC free article: PMC2536973] [PubMed: 864774]
  637. Verschraegen CF, Kudelka AP, Loyer E. et al. A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum. Int J Gynecol Cancer. 98;8(6):494–498. Not relevant to key questions.
  638. Vichinksy EP, Serjeant GR, Davies SC. Understating the morbidity of sickle cell disease [1] (multiple letters) Br J Haematol. 97;99(4):974–978. No Original Data. [PubMed: 9432052]
  639. Vines G. An unsuitable case for treatment. New Sci. 95;147(1994):37–9. No Original Data. [PubMed: 11656470]
  640. Vines G. Gene tests: the parents'' dilemma. New Sci. 94;144(1951):40–4. No Original Data. [PubMed: 11657382]
  641. Voelker R. Cancer drug may join the AIDS arsenal. JAMA. 95;274(7):523. No Original Data. [PubMed: 7629966]
  642. Vokes EE, Ratain MJ, Janisch L. et al. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients [3] EUR J CANCER. 91;27(2):217–218. Not relevant to key questions. [PubMed: 1827293]
  643. Wailoo K. Stigma, race, and disease in 20th century America. Lancet. 2006;367(9509):531–533. No Original Data. [PubMed: 16473131]
  644. Walco GA, Dampier CD. Chronic pain in adolescent patients. J Pediatr Psychol. 87;12(2):215–25. No Original Data. [PubMed: 3612425]
  645. Walker J E. Sickle cell anemia services: do physicians and laymen agree?. IMJ Ill Med J 75;147(6):535–7, 541 Not relevant to key questions. [PubMed: 237811]
  646. Walters MC, Patience M, Leisenring W. et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 96;335(6):369–76. Not relevant to key questions. [PubMed: 8663884]
  647. Wan TS, Ma SK, Chan LC. Acquired pericentric inversion of chromosome 9 in essential thrombocythemia. Hum Genet. 2000;106(6):669–70. Not relevant to key questions. [PubMed: 10942117]
  648. Wang WC. Pain at home in sickle cell disease: an underrecognized problem. J Pediatr Hematol Oncol. 2002;24(8):610–2. Not relevant to key questions, No Original Data. [PubMed: 12439031]
  649. Ware MA, Hambleton I, Ochaya I. et al. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol. 99;104(1):93–6. Not relevant to key questions. [PubMed: 10027718]
  650. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol. 95;50(2):140–3. Study size too small. [PubMed: 7572993]
  651. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 99;94(9):3022–6. Study size too small. [PubMed: 10556185]
  652. Weiner DL, Brugnara C. Hydroxyurea and sickle cell disease: a chance for every patient. JAMA. 2003;289(13):1692–4. No Original Data. [PubMed: 12672739]
  653. Weinlich G, Fritsch P. Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: What is the trigger? [13] Br J Dermatol. 99;141(1):171–172. No Original Data. [PubMed: 10417546]
  654. Weinlich G, Fritsch P. Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: what is the trigger? Br J Dermatol. 99;141(1):171–2. No Original Data. [PubMed: 10417546]
  655. Weissman SB, Sinclair GI, Green CL. et al. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin Infect Dis. 99;29(1):223–224. Not relevant to key questions. [PubMed: 10433603]
  656. Weston GJ, Martin AJ, Mufti GJ. et al. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16(3):157–60. Study size too small. [PMC free article: PMC1586172] [PubMed: 17268588]
  657. Whelan CT, Jin L, Meltzer D. Pain and satisfaction with pain control in hospitalized medical patients: no such thing as low risk. Arch Intern Med. 2004;164(2):175–80. Not relevant to key questions. [PubMed: 14744841]
  658. While AE, Mullen J. Living with sickle cell disease: the perspective of young people. Br J Nurs. 2004;13(6):320–5. Not relevant to key questions, study size too small. [PubMed: 15126965]
  659. Wierenga KJ, Hambleton IR. Comment on: Loureiro & Rozenfeld “Epidemiology of sickle cell disease hospital admissions in Brazil” Rev Saude Publica. 2006;40(4):740–1. author reply 741 Not relevant to key questions, No Original Data. [PubMed: 17063253]
  660. Wilkinson DY. For whose benefit? Politics and sickle cell. Black Scholar. 74;5(8):26–31. Not relevant to key questions, No Original Data. [PubMed: 11661243]
  661. Windrum P, Hull DR, Morris TCM. Herb-drug interactions. Lancet. 2000;355(9208):1019–1020. Not relevant to key questions, No Original Data. [PubMed: 10768466]
  662. Wisdom E. Genetic services for undereserved populations. B. Project funding on local and regional levels: Local funding: The Ohio experience. BIRTH DEFECTS ORIG ARTIC SER. 90;26(2):212–214. Not relevant to key questions, No Original Data. [PubMed: 2094519]
  663. Wong KF, Kwong YL. Isochromosome 8q is a marker of secondary acute myeloid leukemia [1] Cancer Genet Cytogenet. 2000;120(2):171–173. Not relevant to key questions. [PubMed: 10991616]
  664. Wong KF. A novel interstitial deletion of 3p in essential thrombocythemia +AFs-2+AF0- Cancer Genet Cytogenet. 2004;153(1):84–85. Not relevant to key questions, No Original Data. [PubMed: 15325102]
  665. Wonkam A, Angwafo FF. Prenatal diagnosis may represent a point of entry of genetic science in sub-Saharan Africa: A survey on the attitudes of medical students and physicians from Cameroon [8] Prenat Diagn. 2006;26(8):760–761. Not relevant to key questions. [PubMed: 16865743]
  666. Wood BL. Disentangling pathways of effect in family intervention for chronic illness. Fam Syst Health. 2000;18(4):419–422. Not relevant to key questions, No Original Data.
  667. Woods KF, Kutlar A, Johnson JA. et al. Sickle cell telemedicine and standard clinical encounters: a comparison of patient satisfaction. Telemed J. 99;5(4):349–56. Not relevant to key questions. [PubMed: 10908450]
  668. Woofter J C, Anderson P C. Megaloblastic anemia in the management of severe psoriasis. W V Med Not relevant to key questions. [PubMed: 1060245]
  669. Wright J, Bareford D, Wright C. et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol. 2004;126(6):878–80. Not relevant to key questions. [PubMed: 15352993]
  670. Wyatt HV. Improving care for people with sickle cell disease. Health Educ J. 88;47(23):70. No Original Data. [PubMed: 10318195]
  671. Yang YM, Shah AK, Watson M. et al. Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients. Public Health Rep. 95;110(1):80–6. Not relevant to key questions. [PMC free article: PMC1382078] [PubMed: 7838948]
  672. Yasuda N, Ohmori SI, Usui T. Hydroxyurea-induced gangrene of the toes in a patient with chronic myelogenous leukemia [3] Am J Hematol. 2000;63(2):103–104. Not relevant to key questions. [PubMed: 10629580]
  673. Yen A, Freeman L, Fishbaugh J. Hydroxyurea induces precommitment during retinoic induced HL-60 terminal myeloid differentiation: Possible involvement of gene amplification. LEUK RES. 87;11(1):63–71. Not relevant to key questions. [PubMed: 3468316]
  674. Yesley MS. Genetic privacy, discrimination, and social policy: challenges and dilemmas. Microb Comp Genomics. 97;2(1):19–35. Not relevant to key questions, No Original Data. [PubMed: 11660464]
  675. Yoon SL, Black S. Comprehensive, integrative management of pain for patients with sickle-cell disease. J Altern Complement Med. 2006;12(10):995–1001. Not relevant to key questions. [PubMed: 17212571]
  676. Young GAR. Drug-induced haematological disorders. Curr Ther. 84;25(8):61–69. No Original Data.
  677. Young WI, Peters J, Houser HB. et al. Awareness of sickle cell abnormalities. A medical and lay community problem. Ohio State Med J. 74;70(1):27–30. Not relevant to key questions. [PubMed: 4809365]
  678. Yuregir G, Kilinc M, Ekerbicer H. et al. Screening of hemoglobinopathies in Kahramanmaras province (Turkey) situated in a high prevalence area [6] J Trop Pediatr. 2001;47(2):124–125. Not relevant to key questions. [PubMed: 11336135]
  679. Zala C, Salomon H, Cahn P. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea. Antivir Ther. 99;4(Suppl 3):95–9. No Original Data. [PubMed: 16021880]
  680. Zelson JH, O''Brien RT, Pearson HA. A community program for education, testing and counseling for abnormal hemoglobins. Conn Med. 73;37(9):435–9. Not relevant to key questions. [PubMed: 4746165]
  681. Zemlickis D, Lishner M, Degendorfer P. et al. Fetal outcome after in utero exposure to cancer chemotherapy. ARCH INTERN MED. 92;152(3):573–576. Not relevant to key questions. [PubMed: 1546920]
  682. Zielinski WT, Mosher CL. Updating, expanding outpatient facilities. Hospitals. 73;47(3):91–4. passim Not relevant to key questions. [PubMed: 4684333]
  683. Zuazu J, Julia A, Sierra J. et al. Pregnancy outcome in hematologic malignancies. CANCER. 91;67(3):703–709. Not relevant to key questions. [PubMed: 1985762]
  684. Zuniga G, Torres-Bugarin O, Ramirez-Munoz MP. et al. Micronucleated erythrocytes in splenectomized patients with and without chemotherapy. Mutat Res. 96;361(23):107–12. Other, Not relevant to key questions. [PubMed: 8980695]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...